{"status": "ok", "message-type": "work-list", "message-version": "1.0.0", "message": {"facets": {}, "total-results": 437530, "items": [{"indexed": {"date-parts": [[2019, 12, 2]], "date-time": "2019-12-02T15:21:05Z", "timestamp": 1575300065616}, "reference-count": 31, "publisher": "Wiley", "issue": "1", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2015, 9, 1]], "date-time": "2015-09-01T00:00:00Z", "timestamp": 1441065600000}, "delay-in-days": 673, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Br J Haematol"], "published-print": {"date-parts": [[2014, 1]]}, "DOI": "10.1111/bjh.12607", "type": "journal-article", "created": {"date-parts": [[2013, 10, 28]], "date-time": "2013-10-28T08:58:38Z", "timestamp": 1382950718000}, "page": "83-93", "source": "Crossref", "is-referenced-by-count": 20, "title": ["Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia withJAK2-V617F mutation"], "prefix": "10.1111", "volume": "164", "author": [{"given": "Elizabeth", "family": "Hexner", "sequence": "first", "affiliation": [{"name": "University of Pennsylvania; Philadelphia PA USA"}]}, {"given": "Gail", "family": "Roboz", "sequence": "additional", "affiliation": [{"name": "Weill Cornell Medical College; New York NY USA"}]}, {"given": "Ron", "family": "Hoffman", "sequence": "additional", "affiliation": [{"name": "Mount Sinai School of Medicine; Tisch Cancer Institute; New York NY USA"}]}, {"given": "Selina", "family": "Luger", "sequence": "additional", "affiliation": [{"name": "University of Pennsylvania; Philadelphia PA USA"}]}, {"given": "John", "family": "Mascarenhas", "sequence": "additional", "affiliation": [{"name": "Mount Sinai School of Medicine; Tisch Cancer Institute; New York NY USA"}]}, {"given": "Martin", "family": "Carroll", "sequence": "additional", "affiliation": [{"name": "University of Pennsylvania; Philadelphia PA USA"}]}, {"given": "Regina", "family": "Clementi", "sequence": "additional", "affiliation": [{"name": "Teva Branded Pharmaceutical Products R&D, Inc.; Frazer PA USA"}]}, {"given": "Debra", "family": "Bensen-Kennedy", "sequence": "additional", "affiliation": [{"name": "Cephalon, Inc., now a wholly owned subsidiary of Teva Branded Pharmaceutical Products R&D, Inc.; Frazer PA USA"}]}, {"given": "Alison", "family": "Moliterno", "sequence": "additional", "affiliation": [{"name": "Johns Hopkins University School of Medicine; Baltimore MD USA"}]}], "member": "311", "published-online": {"date-parts": [[2013, 10, 28]]}, "reference": [{"key": "10.1111/bjh.12607-BIB0001|bjh12607-cit-0001", "doi-asserted-by": "crossref", "first-page": "1435", "DOI": "10.3324/haematol.2009.021444", "article-title": "Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia", "volume": "95", "author": "Antonioli", "year": "2010", "journal-title": "Haematologica"}, {"key": "10.1111/bjh.12607-BIB0002|bjh12607-cit-0002", "doi-asserted-by": "crossref", "first-page": "1054", "DOI": "10.1016/S0140-6736(05)71142-9", "article-title": "Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders", "volume": "365", "author": "Baxter", "year": "2005", "journal-title": "Lancet"}, {"key": "10.1111/bjh.12607-BIB0003|bjh12607-cit-0003", "doi-asserted-by": "crossref", "first-page": "441", "DOI": "10.1056/NEJM198102193040801", "article-title": "Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy", "volume": "304", "author": "Berk", "year": "1981", "journal-title": "New England Journal of Medicine"}, {"key": "10.1111/bjh.12607-BIB0004|bjh12607-cit-0004", "doi-asserted-by": "crossref", "first-page": "1132", "DOI": "10.1056/NEJM199504273321704", "article-title": "Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis", "volume": "332", "author": "Cortelazzo", "year": "1995", "journal-title": "New England Journal of Medicine"}, {"key": "10.1111/bjh.12607-BIB0005|bjh12607-cit-0005", "doi-asserted-by": "crossref", "first-page": "5227", "DOI": "10.1182/blood-2011-06-363424", "article-title": "EZH2 mutational status predicts poor survival in myelofibrosis", "volume": "118", "author": "Guglielmelli", "year": "2011", "journal-title": "Blood"}, {"key": "10.1111/bjh.12607-BIB0006|bjh12607-cit-0006", "doi-asserted-by": "crossref", "first-page": "33", "DOI": "10.1056/NEJMoa043800", "article-title": "Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia", "volume": "353", "author": "Harrison", "year": "2005", "journal-title": "New England Journal of Medicine"}, {"key": "10.1111/bjh.12607-BIB0007|bjh12607-cit-0007", "doi-asserted-by": "crossref", "first-page": "787", "DOI": "10.1056/NEJMoa1110556", "article-title": "JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis", "volume": "366", "author": "Harrison", "year": "2012", "journal-title": "New England Journal of Medicine"}, {"key": "10.1111/bjh.12607-BIB0008|bjh12607-cit-0008", "doi-asserted-by": "crossref", "first-page": "5663", "DOI": "10.1182/blood-2007-04-083402", "article-title": "Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders", "volume": "111", "author": "Hexner", "year": "2008", "journal-title": "Blood"}, {"key": "10.1111/bjh.12607-BIB0009|bjh12607-cit-0009", "doi-asserted-by": "crossref", "first-page": "1144", "DOI": "10.1038/nature03546", "article-title": "A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera", "volume": "434", "author": "James", "year": "2005", "journal-title": "Nature"}, {"key": "10.1111/bjh.12607-BIB0010|bjh12607-cit-0010", "doi-asserted-by": "crossref", "first-page": "2162", "DOI": "10.1182/blood-2005-03-1320", "article-title": "Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders", "volume": "106", "author": "Jones", "year": "2005", "journal-title": "Blood"}, {"key": "10.1111/bjh.12607-BIB0011|bjh12607-cit-0011", "doi-asserted-by": "crossref", "first-page": "2037", "DOI": "10.1182/blood-2006-03-009860", "article-title": "High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a", "volume": "108", "author": "Kiladjian", "year": "2006", "journal-title": "Blood"}, {"key": "10.1111/bjh.12607-BIB0012|bjh12607-cit-0012", "doi-asserted-by": "crossref", "first-page": "3065", "DOI": "10.1182/blood-2008-03-143537", "article-title": "Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera", "volume": "112", "author": "Kiladjian", "year": "2008", "journal-title": "Blood"}, {"key": "10.1111/bjh.12607-BIB0013|bjh12607-cit-0013", "doi-asserted-by": "crossref", "first-page": "602", "DOI": "10.1309/AJCPPPZ1WFVGNE4A", "article-title": "Molecular pathology of myeloproliferative neoplasms", "volume": "133", "author": "Klco", "year": "2010", "journal-title": "American Journal of Clinical Pathology"}, {"key": "10.1111/bjh.12607-BIB0014|bjh12607-cit-0014", "doi-asserted-by": "crossref", "first-page": "1779", "DOI": "10.1056/NEJMoa051113", "article-title": "A gain-of-function mutation of JAK2 in myeloproliferative disorders", "volume": "352", "author": "Kralovics", "year": "2005", "journal-title": "New England Journal of Medicine"}, {"key": "10.1111/bjh.12607-BIB0015|bjh12607-cit-0015", "doi-asserted-by": "crossref", "first-page": "114", "DOI": "10.1056/NEJMoa035572", "article-title": "Efficacy and safety of low-dose aspirin in polycythemia vera", "volume": "350", "author": "Landolfi", "year": "2004", "journal-title": "New England Journal of Medicine"}, {"key": "10.1111/bjh.12607-BIB0016|bjh12607-cit-0016", "doi-asserted-by": "crossref", "first-page": "387", "DOI": "10.1016/j.ccr.2005.03.023", "article-title": "Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis", "volume": "7", "author": "Levine", "year": "2005", "journal-title": "Cancer Cell"}, {"key": "10.1111/bjh.12607-BIB0017|bjh12607-cit-0017", "doi-asserted-by": "crossref", "first-page": "3294", "DOI": "10.1182/blood-2010-08-301796", "article-title": "Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse", "volume": "117", "author": "Levis", "year": "2011", "journal-title": "Blood"}, {"key": "10.1111/bjh.12607-BIB0018|bjh12607-cit-0018", "doi-asserted-by": "crossref", "first-page": "1528", "DOI": "10.1182/blood-2009-12-259747", "article-title": "JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia", "volume": "116", "author": "Li", "year": "2010", "journal-title": "Blood"}, {"key": "10.1111/bjh.12607-BIB0019|bjh12607-cit-0019", "doi-asserted-by": "crossref", "first-page": "3913", "DOI": "10.1182/blood-2006-03-008805", "article-title": "Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression", "volume": "108", "author": "Moliterno", "year": "2006", "journal-title": "Blood"}, {"key": "10.1111/bjh.12607-BIB0020|bjh12607-cit-0020", "doi-asserted-by": "crossref", "first-page": "1480", "DOI": "10.1016/j.exphem.2008.05.006", "article-title": "Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens", "volume": "36", "author": "Moliterno", "year": "2008", "journal-title": "Experimental Hematology"}, {"key": "10.1111/bjh.12607-BIB0021|bjh12607-cit-0021", "doi-asserted-by": "crossref", "first-page": "789", "DOI": "10.1200/JCO.2010.32.8021", "article-title": "Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis", "volume": "29", "author": "Pardanani", "year": "2011", "journal-title": "Journal of Clinical Oncology"}, {"key": "10.1111/bjh.12607-BIB0022|bjh12607-cit-0022", "doi-asserted-by": "crossref", "first-page": "1131", "DOI": "10.1182/blood-2009-10-246363", "article-title": "Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis", "volume": "115", "author": "Santos", "year": "2010", "journal-title": "Blood"}, {"key": "10.1111/bjh.12607-BIB0023|bjh12607-cit-0023", "doi-asserted-by": "crossref", "first-page": "2435", "DOI": "10.1182/blood-2006-04-018259", "article-title": "Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia", "volume": "108", "author": "Scott", "year": "2006", "journal-title": "Blood"}, {"key": "10.1111/bjh.12607-BIB0024|bjh12607-cit-0024", "doi-asserted-by": "crossref", "first-page": "2513", "DOI": "10.1001/jama.2010.853", "article-title": "Primary myelofibrosis and the myeloproliferative neoplasms: the role of individual variation. JAMA: the", "volume": "303", "author": "Stein", "year": "2010", "journal-title": "Journal of the American Medical Association"}, {"key": "10.1111/bjh.12607-BIB0025|bjh12607-cit-0025", "doi-asserted-by": "crossref", "first-page": "1090", "DOI": "10.3324/haematol.2009.014407", "article-title": "Sex differences in the JAK2 V617F allele burden in chronic myeloproliferative disorders", "volume": "95", "author": "Stein", "year": "2010", "journal-title": "Haematologica"}, {"key": "10.1111/bjh.12607-BIB0026|bjh12607-cit-0026", "doi-asserted-by": "crossref", "first-page": "1462", "DOI": "10.3324/haematol.2011.045591", "article-title": "Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes", "volume": "96", "author": "Stein", "year": "2011", "journal-title": "Haematologica"}, {"key": "10.1111/bjh.12607-BIB0027|bjh12607-cit-0027", "doi-asserted-by": "crossref", "first-page": "179", "DOI": "10.1016/j.exphem.2003.11.003", "article-title": "Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera", "volume": "32", "author": "Ugo", "year": "2004", "journal-title": "Experimental Hematology"}, {"key": "10.1111/bjh.12607-BIB0028|bjh12607-cit-0028", "doi-asserted-by": "crossref", "first-page": "1299", "DOI": "10.1038/leu.2008.113", "article-title": "Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal", "volume": "22", "author": "Vannucchi", "year": "2008", "journal-title": "Leukemia"}, {"key": "10.1111/bjh.12607-BIB0029|bjh12607-cit-0029", "doi-asserted-by": "crossref", "first-page": "636", "DOI": "10.1182/asheducation-2009.1.636", "article-title": "Therapeutic potential of JAK2 inhibitors", "volume": "2009", "author": "Verstovsek", "year": "2009", "journal-title": "Hematology: American Society of Hematology Education Program"}, {"key": "10.1111/bjh.12607-BIB0030|bjh12607-cit-0030", "doi-asserted-by": "crossref", "first-page": "799", "DOI": "10.1056/NEJMoa1110557", "article-title": "A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis", "volume": "366", "author": "Verstovsek", "year": "2012", "journal-title": "New England Journal of Medicine"}, {"key": "10.1111/bjh.12607-BIB0031|bjh12607-cit-0031", "doi-asserted-by": "crossref", "first-page": "e18", "DOI": "10.3324/haematol.2010.037846", "article-title": "Hydroxyurea dose impacts hematologic parameters in polycythemia vera and essential thrombocythemia but does not appreciably affect JAK2-V617F allele burden", "volume": "96", "author": "Zalcberg", "year": "2011", "journal-title": "Haematologica"}], "container-title": ["British Journal of Haematology"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fbjh.12607", "content-type": "unspecified", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2017, 6, 22]], "date-time": "2017-06-22T00:53:33Z", "timestamp": 1498092813000}, "score": 90.18333, "issued": {"date-parts": [[2013, 10, 28]]}, "references-count": 31, "journal-issue": {"published-print": {"date-parts": [[2014, 1]]}, "issue": "1"}, "URL": "http://dx.doi.org/10.1111/bjh.12607", "relation": {"cites": []}, "ISSN": ["0007-1048"], "issn-type": [{"value": "0007-1048", "type": "print"}], "subject": ["Hematology"]}, {"indexed": {"date-parts": [[2019, 12, 5]], "date-time": "2019-12-05T07:22:41Z", "timestamp": 1575530561350}, "reference-count": 0, "publisher": "American Society of Hematology", "issue": "11", "content-domain": {"domain": ["ashpublications.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[2008, 11, 16]]}, "abstract": "<jats:title>Abstract</jats:title>\n               <jats:p>Polycythemia vera (PV) and essential thrombocytosis (ET) are clonal hematopoietic stem cell disorders characterized by the over production of phenotypically normal circulating blood cells. Most PV and approximately half of ET patients harbor the activating mutation JAK2 V617F. CEP-701 is an orally available, potent low nanomolar inhibitor of both the wild-type and mutated JAK2 tyrosine kinase, with its inhibitory effect demonstrated both in enzymatic and cellular assays and in vivo, where CEP-701 significantly inhibited the growth of JAK2 V617F-positive HEL.92 xenografts in mice. These findings suggest that CEP-701 is an attractive candidate for clinical evaluation in JAK2 V617F-positive myeloproliferative disorders. The purpose of this study is to test the safety and efficacy of CEP-701 administration in JAK2 V617F positive ET and PV patients. The primary endpoint is reduction in JAK2 V617F neutrophil allele burden; secondary endpoints are reduction in phlebotomy rates, improvement in hemoglobin, white cell and platelet counts, reduction in hydroxyurea (HU) dose, and reduction in spleen size. The secondary endpoints include the pharmacokinetics and pharmacodynamics of CEP-701 and the safety of CEP-701 treatment in patients with JAK2 V617F-positive PV and ET. This is a multicenter study with an anticipated enrollment of 40 PV and ET patients. Inclusion criteria include JAK2 V617F-positive PV and ET patients; patients with PV either have a neutrophil count greater than 7,000/ul or are receiving HU, while ET patients are receiving concomitant HU. Other inclusion criteria include an ECOG performance status of 0, 1 or 2, and 18 years of age or older. Exclusion criteria include the active use of anegrelide or interferon, or a recent history of venous or arterial thrombosis. This is an 18 week trial with an optional 1 year extension period; doses will escalate from 80 mg twice daily to a maximum of 120 mg twice daily. To date, 20 subjects, 11 PV and 9 ET, comprised of 11 females and 9 males, ages 34 to 74, have enrolled. Approximately 27% of the PV patients were taking HU. The most common adverse events have been gastrointestinal (GI) and constitutional in nature. No related serious adverse events have been observed. Five patients have discontinued study participation, all for adverse events: 1 due to disease progression, 1 leg cramps, and 3 GI. To date, 7 patients have completed 18 weeks of therapy and 6 of these patients will continue to receive CEP-701 on the extension phase of the trial. Five of 8 subjects with splenomegaly have responded with reductions in spleen size evident within 6 weeks of therapy initiation. Updated results on current and future patients will be presented at the meeting.</jats:p>", "DOI": "10.1182/blood.v112.11.99.99", "type": "journal-article", "created": {"date-parts": [[2019, 10, 13]], "date-time": "2019-10-13T15:18:44Z", "timestamp": 1570979924000}, "page": "99-99", "update-policy": "http://dx.doi.org/10.1182/blood.2019cm0000", "source": "Crossref", "is-referenced-by-count": 2, "title": ["An Open-Label Study of CEP-701 in Patients with JAK2 V617F-Positive Polycythemia Vera and Essential Thrombocytosis"], "prefix": "10.1182", "volume": "112", "author": [{"given": "Alison R", "family": "Moliterno", "sequence": "first", "affiliation": [{"name": "Medicine, Johns Hopkins University School of Medicince, Baltimore, MD, USA"}]}, {"given": "Gail J.", "family": "Roboz", "sequence": "additional", "affiliation": [{"name": "Medicine, Weill Cornell Medical College, New York, NY, USA"}]}, {"given": "Martin", "family": "Carroll", "sequence": "additional", "affiliation": [{"name": "Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA"}]}, {"given": "Selina", "family": "Luger", "sequence": "additional", "affiliation": [{"name": "Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA"}]}, {"given": "Elizabeth", "family": "Hexner", "sequence": "additional", "affiliation": [{"name": "University of Pennsylvania, Philadelphia, PA, USA"}]}, {"given": "Debra M.", "family": "Bensen-Kennedy", "sequence": "additional", "affiliation": [{"name": "Cephalon, Frazer, PA, USA"}]}], "member": "234", "container-title": ["Blood"], "language": "en", "link": [{"URL": "https://ashpublications.org/blood/article/112/11/99/74854/An-OpenLabel-Study-of-CEP701-in-Patients-with-JAK2", "content-type": "application/pdf", "content-version": "vor", "intended-application": "syndication"}, {"URL": "https://ashpublications.org/blood/article/112/11/99/74854/An-OpenLabel-Study-of-CEP701-in-Patients-with-JAK2", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 17]], "date-time": "2019-11-17T19:38:41Z", "timestamp": 1574019521000}, "score": 62.790417, "issued": {"date-parts": [[2008, 11, 16]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2008, 11, 16]]}, "issue": "11"}, "URL": "http://dx.doi.org/10.1182/blood.v112.11.99.99", "ISSN": ["0006-4971", "1528-0020"], "issn-type": [{"value": "0006-4971", "type": "print"}, {"value": "1528-0020", "type": "electronic"}], "subject": ["Immunology", "Cell Biology", "Biochemistry", "Hematology"]}, {"indexed": {"date-parts": [[2019, 12, 5]], "date-time": "2019-12-05T06:34:43Z", "timestamp": 1575527683334}, "reference-count": 0, "publisher": "American Society of Hematology", "issue": "22", "content-domain": {"domain": ["ashpublications.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[2009, 11, 20]]}, "abstract": "<jats:title>Abstract</jats:title>\n               <jats:p>Abstract 753</jats:p>\n               <jats:p>Since the seminal discovery of the JAK2V617F mutation, small molecule inhibitors of JAK2 to treat patients with myeloproliferative neoplasms have been recently evaluated in a growing number of clinical trials. To date, there has been limited evaluation of the utility of such JAK2 inhibitors in patients with PV or ET. CEP-701 is an orally available, potent, low nanomolar inhibitor of both the wild-type and mutated JAK2 tyrosine kinase, with its inhibitory effect being demonstrated both in enzymatic and cellular assays. The present study is the first JAK2 inhibitor study to test the safety and efficacy of such an agent in high risk JAK2 V617F positive ET and PV patients. The primary endpoint was reduction in JAK2 V617F neutrophil allele burden. Secondary endpoints included reduction in phlebotomy rates; improvement in hemoglobin, white cell and platelet counts; reduction in hydroxyurea (HU) dose and spleen size; and the pharmacokinetics and pharmacodynamics of CEP-701. Enrollment was completed with 39 JAK2V617F-positive subjects, 27 PV and 12 ET, 22 females and 17 males, ages 38 to 80. The PV patients were a high risk group as defined by a median age of 65 years, neutrophil JAK2V617F allele burden of 76%, prevalence of prior thrombotic events of 19%, prior HU use in 44% and an average white cell count of 19,600/ul (range 3,500-78,600). The ET patients were also considered to be a high risk group as defined by a median age of 61.5 years, the prior use of HU in 100% of cases, and prevalence of prior thrombotic events of 25%; the median neutrophil JAK2V617F allele burden was 40%. More than half the patients had had their disease for 5 years or longer. To date, 15 of the patients have completed 18 weeks of treatment and 13 of these patients continue on the extension phase of the trial. Within 18 weeks, responses included a reduction spleen size of &gt; 5cm or to non-palpable in 15/18 (83%) subjects and amelioration of pruritus in 5/5 patients studied. While reduction in phlebotomy requirement occurred in a number of phlebotomy dependent patients (3/5 evaluable at time of report), this effect was not evident in these patients until 6 months of therapy, and was not associated with concomitant reductions in white cell or platelet count. In fact, in many patients, platelet and white cell counts increased while on drug. A reduction in the JAK2 V617F allele burden of 15% or more was observed in 3 of the 15 patients at the 18 week assessment. The most common adverse events were gastrointestinal, which were dose related and improved over time. Serious adverse events have occurred, including 5 patients experiencing thrombotic events (3 venous (1 DVT, 1DVT/PE, 1 PVT), 2 arterial (1 TIA, 1 PAT)), and one non-serious DVT. We conclude that CEP-701 is biologically active agent in patients with JAK2 V617F positive PV and ET. Serious adverse events related to thrombosis, however, have occurred which to date have not been reported with the use of other JAK2 inhibitor trials involving patients with PMF. Though substantial symptomatic improvements have occurred, our data suggest, at a minimum, that JAK2 inhibitor therapy may not prevent thrombosis in high-risk patients with PV and ET. This risk of thrombosis may be a disease specific interaction in PV and ET patients since thrombosis has not been a frequent complication of CEP 701 therapy for other malignancies. Final 18 week data and cumulative extension data will be updated at the annual meeting.</jats:p>\n               <jats:sec>\n                  <jats:title>Disclosures:</jats:title>\n                  <jats:p>Roboz: Cephalon: Consultancy. Carroll:Cephalon consultancy: Consultancy; Sanofi Aventis Corporation: Research Funding; Kyowa Hakko Kirin Pharmaceutical: Research Funding. Bensen-Kennedy:cephalon: Employment.</jats:p>\n               </jats:sec>", "DOI": "10.1182/blood.v114.22.753.753", "type": "journal-article", "created": {"date-parts": [[2019, 10, 9]], "date-time": "2019-10-09T21:18:46Z", "timestamp": 1570655926000}, "page": "753-753", "update-policy": "http://dx.doi.org/10.1182/blood.2019cm0000", "source": "Crossref", "is-referenced-by-count": 3, "title": ["An Open-Label Study of CEP-701 in Patients with JAK2 V617F-Positive PV and ET: Update of 39 Enrolled Patients."], "prefix": "10.1182", "volume": "114", "author": [{"given": "Alison R", "family": "Moliterno", "sequence": "first", "affiliation": [{"name": "Medicine, Johns Hopkins University School of Medicince, Baltimore, MD, USA,"}]}, {"given": "Elizabeth", "family": "Hexner", "sequence": "additional", "affiliation": [{"name": "3400 Civic Center Boulevard, University of Pennsylvania, Philadelphia, PA, USA,"}]}, {"given": "Gail J.", "family": "Roboz", "sequence": "additional", "affiliation": [{"name": "Department of Medicine, Leukemia Program, Weill-Cornell College of Medicine, New York, NY, USA,"}]}, {"given": "Martin", "family": "Carroll", "sequence": "additional", "affiliation": [{"name": "Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA,"}]}, {"given": "Selina", "family": "Luger", "sequence": "additional", "affiliation": [{"name": "Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA,"}]}, {"given": "John", "family": "Mascarenhas", "sequence": "additional", "affiliation": [{"name": "Department of Medicine, Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY, USA,"}]}, {"given": "Ronald", "family": "Hoffman", "sequence": "additional", "affiliation": [{"name": "Department of Medicine, Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY, USA,"}]}, {"given": "Debra M", "family": "Bensen-Kennedy", "sequence": "additional", "affiliation": [{"name": "Cephalon, Frazer, PA"}]}], "member": "234", "container-title": ["Blood"], "language": "en", "link": [{"URL": "https://ashpublications.org/blood/article/114/22/753/65395/An-OpenLabel-Study-of-CEP701-in-Patients-with-JAK2", "content-type": "application/pdf", "content-version": "vor", "intended-application": "syndication"}, {"URL": "https://ashpublications.org/blood/article/114/22/753/65395/An-OpenLabel-Study-of-CEP701-in-Patients-with-JAK2", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 16]], "date-time": "2019-11-16T08:03:11Z", "timestamp": 1573891391000}, "score": 52.36001, "issued": {"date-parts": [[2009, 11, 20]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2009, 11, 20]]}, "issue": "22"}, "URL": "http://dx.doi.org/10.1182/blood.v114.22.753.753", "ISSN": ["0006-4971", "1528-0020"], "issn-type": [{"value": "0006-4971", "type": "print"}, {"value": "1528-0020", "type": "electronic"}], "subject": ["Immunology", "Cell Biology", "Biochemistry", "Hematology"]}, {"indexed": {"date-parts": [[2019, 11, 21]], "date-time": "2019-11-21T06:41:00Z", "timestamp": 1574318460074}, "reference-count": 0, "publisher": "Elsevier BV", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2007, 8, 1]], "date-time": "2007-08-01T00:00:00Z", "timestamp": 1185926400000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Blood Reviews"], "published-print": {"date-parts": [[2007, 8]]}, "DOI": "10.1016/s0268-960x(07)70192-3", "type": "journal-article", "created": {"date-parts": [[2007, 8, 27]], "date-time": "2007-08-27T11:10:10Z", "timestamp": 1188213010000}, "page": "S123", "source": "Crossref", "is-referenced-by-count": 0, "title": ["P114 JAK2 mutation in polycythaemia vera and essential thrombocythaemia"], "prefix": "10.1016", "volume": "21", "author": [{"given": "P.", "family": "Batar", "sequence": "first", "affiliation": []}, {"given": "E.", "family": "Kelemen", "sequence": "additional", "affiliation": []}, {"given": "B.", "family": "Telek", "sequence": "additional", "affiliation": []}, {"given": "Gy.", "family": "Remenyi", "sequence": "additional", "affiliation": []}, {"given": "A.", "family": "Kiss", "sequence": "additional", "affiliation": []}, {"given": "L.", "family": "Rejto", "sequence": "additional", "affiliation": []}, {"given": "M.", "family": "Udvardy", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Blood Reviews"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0268960X07701923?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0268960X07701923?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 1, 4]], "date-time": "2019-01-04T23:57:01Z", "timestamp": 1546646221000}, "score": 51.80185, "issued": {"date-parts": [[2007, 8]]}, "references-count": 0, "alternative-id": ["S0268960X07701923"], "URL": "http://dx.doi.org/10.1016/s0268-960x(07)70192-3", "ISSN": ["0268-960X"], "issn-type": [{"value": "0268-960X", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 12, 2]], "date-time": "2019-12-02T08:16:17Z", "timestamp": 1575274577241}, "reference-count": 9, "publisher": "Elsevier BV", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2018, 6, 1]], "date-time": "2018-06-01T00:00:00Z", "timestamp": 1527811200000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": ["ejinme.com", "clinicalkey.jp", "clinicalkey.com", "clinicalkey.es", "clinicalkey.com.au", "clinicalkey.fr", "elsevier.com", "sciencedirect.com"], "crossmark-restriction": true}, "short-container-title": ["European Journal of Internal Medicine"], "published-print": {"date-parts": [[2018, 6]]}, "DOI": "10.1016/j.ejim.2018.03.017", "type": "journal-article", "created": {"date-parts": [[2018, 4, 3]], "date-time": "2018-04-03T14:01:16Z", "timestamp": 1522764076000}, "page": "e37-e38", "update-policy": "http://dx.doi.org/10.1016/elsevier_cm_policy", "source": "Crossref", "is-referenced-by-count": 0, "title": ["An increase in diagnostic JAK2 V617F mutation testing: Is masked polycythaemia vera the explanantion?"], "prefix": "10.1016", "volume": "52", "author": [{"given": "Stephen E.", "family": "Langabeer", "sequence": "first", "affiliation": []}], "member": "78", "container-title": ["European Journal of Internal Medicine"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0953620518301353?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0953620518301353?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 10, 4]], "date-time": "2018-10-04T00:11:51Z", "timestamp": 1538611911000}, "score": 46.84074, "issued": {"date-parts": [[2018, 6]]}, "references-count": 9, "alternative-id": ["S0953620518301353"], "URL": "http://dx.doi.org/10.1016/j.ejim.2018.03.017", "ISSN": ["0953-6205"], "issn-type": [{"value": "0953-6205", "type": "print"}], "subject": ["Internal Medicine"], "assertion": [{"value": "Elsevier", "name": "publisher", "label": "This article is maintained by"}, {"value": "An increase in diagnostic JAK2 V617F mutation testing: Is masked polycythaemia vera the explanantion?", "name": "articletitle", "label": "Article Title"}, {"value": "European Journal of Internal Medicine", "name": "journaltitle", "label": "Journal Title"}, {"value": "https://doi.org/10.1016/j.ejim.2018.03.017", "name": "articlelink", "label": "CrossRef DOI link to publisher maintained version"}, {"value": "simple-article", "name": "content_type", "label": "Content Type"}, {"value": "\u00a9 2018 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.", "name": "copyright", "label": "Copyright"}]}, {"indexed": {"date-parts": [[2019, 11, 21]], "date-time": "2019-11-21T05:29:47Z", "timestamp": 1574314187057}, "reference-count": 41, "publisher": "Ovid Technologies (Wolters Kluwer Health)", "issue": "5", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Current Opinion in Hematology"], "published-print": {"date-parts": [[2007, 9]]}, "DOI": "10.1097/moh.0b013e3282861d1b", "type": "journal-article", "created": {"date-parts": [[2007, 8, 1]], "date-time": "2007-08-01T07:01:21Z", "timestamp": 1185951681000}, "page": "450-454", "source": "Crossref", "is-referenced-by-count": 22, "title": ["JAK2 V617F: implications for thrombosis in myeloproliferative diseases"], "prefix": "10.1097", "volume": "14", "author": [{"given": "Elizabeth O", "family": "Hexner", "sequence": "first", "affiliation": []}], "member": "276", "container-title": ["Current Opinion in Hematology"], "language": "en", "deposited": {"date-parts": [[2019, 2, 2]], "date-time": "2019-02-02T20:40:44Z", "timestamp": 1549140044000}, "score": 38.835915, "subtitle": [""], "issued": {"date-parts": [[2007, 9]]}, "references-count": 41, "journal-issue": {"issue": "5"}, "URL": "http://dx.doi.org/10.1097/moh.0b013e3282861d1b", "ISSN": ["1065-6251"], "issn-type": [{"value": "1065-6251", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 22]], "date-time": "2019-11-22T09:27:58Z", "timestamp": 1574414878109}, "reference-count": 23, "publisher": "Wiley", "issue": "2", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2015, 9, 1]], "date-time": "2015-09-01T00:00:00Z", "timestamp": 1441065600000}, "delay-in-days": 1673, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2011, 2]]}, "DOI": "10.1111/j.1445-5994.2010.02199.x", "type": "journal-article", "created": {"date-parts": [[2010, 2, 26]], "date-time": "2010-02-26T11:05:56Z", "timestamp": 1267182356000}, "page": "191-196", "source": "Crossref", "is-referenced-by-count": 4, "title": ["JAK2 mutations in Asian patients with essential thrombocythaemia"], "prefix": "10.1111", "volume": "41", "author": [{"given": "G-C.", "family": "Wong", "sequence": "first", "affiliation": []}, {"given": "G. L. S.", "family": "Kam", "sequence": "additional", "affiliation": []}, {"given": "E. S. C.", "family": "Koay", "sequence": "additional", "affiliation": []}], "member": "311", "published-online": {"date-parts": [[2011, 2, 25]]}, "reference": [{"key": "10.1111/j.1445-5994.2010.02199.x-BIB1|cit1", "author": "Spivak", "first-page": "200", "year": "2003", "article-title": "Chronic myeloproliferative disorders", "journal-title": "Hematology Am Soc Hematol Educ Program", "DOI": "10.1182/asheducation-2003.1.200", "doi-asserted-by": "crossref"}, {"key": "10.1111/j.1445-5994.2010.02199.x-BIB2|cit2", "doi-asserted-by": "crossref", "first-page": "1054", "DOI": "10.1016/S0140-6736(05)74230-6", "article-title": "Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders", "volume": "365", "author": "Baxter", "year": "2005", "journal-title": "Lancet"}, {"key": "10.1111/j.1445-5994.2010.02199.x-BIB3|cit3", "doi-asserted-by": "crossref", "first-page": "1779", "DOI": "10.1056/NEJMoa051113", "article-title": "A gain-of-function mutation of JAK2 in myeloproliferative disorders", "volume": "352", "author": "Kralovics", "year": "2005", "journal-title": "N Engl J Med"}, {"key": "10.1111/j.1445-5994.2010.02199.x-BIB4|cit4", "doi-asserted-by": "crossref", "first-page": "387", "DOI": "10.1016/j.ccr.2005.03.023", "article-title": "Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis", "volume": "7", "author": "Levine", "year": "2005", "journal-title": "Cancer Cell"}, {"key": "10.1111/j.1445-5994.2010.02199.x-BIB5|cit5", "doi-asserted-by": "crossref", "first-page": "2162", "DOI": "10.1182/blood-2005-03-1320", "article-title": "Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders", "volume": "106", "author": "Jones", "year": "2005", "journal-title": "Blood"}, {"key": "10.1111/j.1445-5994.2010.02199.x-BIB6|cit6", "doi-asserted-by": "crossref", "first-page": "22788", "DOI": "10.1074/jbc.C500138200", "article-title": "Identification of an acquired JAK2 mutation in polycythemia vera", "volume": "280", "author": "Zhao", "year": "2005", "journal-title": "J Biol Chem"}, {"key": "10.1111/j.1445-5994.2010.02199.x-BIB7|cit7", "doi-asserted-by": "crossref", "first-page": "1847", "DOI": "10.1038/sj.leu.2403902", "article-title": "Clinical implications of the JAK2-V617F mutation in essential thrombocythemia", "volume": "19", "author": "Antonioli", "year": "2005", "journal-title": "Leukemia"}, {"key": "10.1111/j.1445-5994.2010.02199.x-BIB8|cit8", "doi-asserted-by": "crossref", "first-page": "1945", "DOI": "10.1016/S0140-6736(05)67785-9", "article-title": "Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study", "volume": "366", "author": "Campbell", "year": "2005", "journal-title": "Lancet"}, {"key": "10.1111/j.1445-5994.2010.02199.x-BIB9|cit9", "doi-asserted-by": "crossref", "first-page": "208", "DOI": "10.1111/j.1365-2141.2005.05764.x", "article-title": "JAK2V617F mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance", "volume": "131", "author": "Wolanskyj", "year": "2005", "journal-title": "Br J Haematol"}, {"key": "10.1111/j.1445-5994.2010.02199.x-BIB10|cit10", "doi-asserted-by": "crossref", "first-page": "320", "DOI": "10.1111/j.1365-2141.2005.05776.x", "article-title": "The JAK2 V617F tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates", "volume": "131", "author": "Tefferi", "year": "2005", "journal-title": "Br J Haematol"}, {"key": "10.1111/j.1445-5994.2010.02199.x-BIB11|cit11", "doi-asserted-by": "crossref", "first-page": "4198", "DOI": "10.1182/blood-2003-10-3471", "article-title": "Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin", "volume": "103", "author": "Ding", "year": "2004", "journal-title": "Blood"}, {"key": "10.1111/j.1445-5994.2010.02199.x-BIB12|cit12", "doi-asserted-by": "crossref", "first-page": "1053", "DOI": "10.1016/j.leukres.2006.09.005", "article-title": "Correlations of JAK2-V617F mutation with clinical and laboratory findings in patients with myeloproliferative disorders", "volume": "31", "author": "Speletas", "year": "2007", "journal-title": "Leuk Res"}, {"key": "10.1111/j.1445-5994.2010.02199.x-BIB13|cit13", "doi-asserted-by": "crossref", "first-page": "244", "DOI": "10.1111/j.1365-2141.2005.05858.x", "article-title": "The presence of the JAK2 V618F mutation is associated with a higher haemaglobin and increased risk of thrombosis in essential thrombocythaemia", "volume": "132", "author": "Cheung", "year": "2005", "journal-title": "Br J Haematol"}, {"key": "10.1111/j.1445-5994.2010.02199.x-BIB14|cit14", "doi-asserted-by": "crossref", "first-page": "135", "DOI": "10.3324/haematol.10634", "article-title": "Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status", "volume": "92", "author": "Finazzi", "year": "2007", "journal-title": "Haematologica"}, {"key": "10.1111/j.1445-5994.2010.02199.x-BIB15|cit15", "doi-asserted-by": "crossref", "first-page": "219", "DOI": "10.3904/kjim.2006.21.4.219", "article-title": "Diagnostic usefulness of the Janus kinase 2 mutation in non BCR/ABL myeloproliferative disorders", "volume": "21", "author": "Bang", "year": "2006", "journal-title": "Korean J Intern Med"}, {"key": "10.1111/j.1445-5994.2010.02199.x-BIB16|cit16", "doi-asserted-by": "crossref", "first-page": "458", "DOI": "10.1002/ajh.20872", "article-title": "Analysis of JAK2 V617F mutation in Chinese patients with myeloproliferative disorders", "volume": "82", "author": "Chen", "year": "2007", "journal-title": "Am J Hematol"}, {"key": "10.1111/j.1445-5994.2010.02199.x-BIB17|cit17", "doi-asserted-by": "crossref", "first-page": "422", "DOI": "10.1111/j.1445-5994.2007.01589.x", "article-title": "Prevalence of the JAK2-V617F mutation in Taiwanese patients with chronic myeloproliferative disorders", "volume": "38", "author": "Lieu", "year": "2008", "journal-title": "Intern Med J"}, {"key": "10.1111/j.1445-5994.2010.02199.x-BIB18|cit18", "author": "Murphy", "first-page": "29", "year": "1997", "article-title": "Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival and leukemic transition by treatment", "journal-title": "Semin Hematol"}, {"key": "10.1111/j.1445-5994.2010.02199.x-BIB19|cit19", "author": "Imbert", "first-page": "39", "year": "2001", "volume-title": "WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues"}, {"key": "10.1111/j.1445-5994.2010.02199.x-BIB20|cit20", "author": "Tefferi", "first-page": "172", "year": "1999", "article-title": "Risk-based management in essential thrombocythemia", "journal-title": "Am Soc Hematol Educ Prog Book"}, {"key": "10.1111/j.1445-5994.2010.02199.x-BIB21|cit21", "first-page": "253", "article-title": "Methods for the detection of the JAK2 V617F mutation in human myeloproliferative disorders", "volume": "125", "author": "Campbell", "year": "2006", "journal-title": "Methods Mol Med"}, {"key": "10.1111/j.1445-5994.2010.02199.x-BIB22|cit22", "doi-asserted-by": "crossref", "first-page": "902", "DOI": "10.1111/j.1365-2141.2008.07127.x", "article-title": "JAK2 V617F mutation is associated with increased risk of thrombosis in Chinese patients with essential thrombocythaemia", "volume": "141", "author": "Wong", "year": "2008", "journal-title": "Br J Haematol"}, {"key": "10.1111/j.1445-5994.2010.02199.x-BIB23|cit23", "first-page": "114a", "article-title": "Distinct hemostatic profile of leukocytes in essential thrombocythemia (ET) carrying the JAK2 V617F mutation", "volume": "106", "author": "Falanga", "year": "2005", "journal-title": "Blood"}], "container-title": ["Internal Medicine Journal"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1445-5994.2010.02199.x", "content-type": "unspecified", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 5, 26]], "date-time": "2019-05-26T12:25:38Z", "timestamp": 1558873538000}, "score": 37.21399, "subtitle": ["JAK2 mutations in Asian patients with ET"], "issued": {"date-parts": [[2011, 2]]}, "references-count": 23, "journal-issue": {"published-print": {"date-parts": [[2011, 2]]}, "issue": "2"}, "URL": "http://dx.doi.org/10.1111/j.1445-5994.2010.02199.x", "archive": ["Portico"], "relation": {"cites": []}, "ISSN": ["1444-0903"], "issn-type": [{"value": "1444-0903", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 12, 5]], "date-time": "2019-12-05T13:11:15Z", "timestamp": 1575551475815}, "reference-count": 10, "publisher": "Wiley", "license": [{"URL": "http://onlinelibrary.wiley.com/termsAndConditions#vor", "start": {"date-parts": [[2019, 11, 19]], "date-time": "2019-11-19T00:00:00Z", "timestamp": 1574121600000}, "delay-in-days": 0, "content-version": "vor"}, {"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2019, 11, 19]], "date-time": "2019-11-19T00:00:00Z", "timestamp": 1574121600000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": ["onlinelibrary.wiley.com"], "crossmark-restriction": true}, "short-container-title": ["Breast J"], "DOI": "10.1111/tbj.13683", "type": "journal-article", "created": {"date-parts": [[2019, 11, 19]], "date-time": "2019-11-19T18:48:23Z", "timestamp": 1574189303000}, "update-policy": "http://dx.doi.org/10.1002/crossmark_policy", "source": "Crossref", "is-referenced-by-count": 0, "title": ["The\n            JAK2\n            V617F mutation in breast cancer?"], "prefix": "10.1111", "author": [{"ORCID": "http://orcid.org/0000-0002-6119-158X", "authenticated-orcid": false, "given": "Stephen E.", "family": "Langabeer", "sequence": "first", "affiliation": [{"name": "St. James's Hospital Dublin Ireland"}]}], "member": "311", "published-online": {"date-parts": [[2019, 11, 19]]}, "reference": [{"key": "e_1_2_2_2_1", "author": "Naeem MA", "year": "2019", "article-title": "Detection of JAK2 gene mutation in Pakistani women with triple\u2010negative breast cancer", "journal-title": "Breast J"}, {"key": "e_1_2_2_3_1", "doi-asserted-by": "crossref", "first-page": "2920", "DOI": "10.1182/blood-2005-05-2087", "article-title": "The V617F mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders", "volume": "106", "author": "Scott LM", "year": "2005", "journal-title": "Blood"}, {"key": "e_1_2_2_4_1", "doi-asserted-by": "crossref", "first-page": "1434", "DOI": "10.1038/sj.onc.1209163", "article-title": "The JAK2 V617F mutation in de novo acute myelogenous leukemias", "volume": "25", "author": "Lee JW", "year": "2006", "journal-title": "Oncogene"}, {"key": "e_1_2_2_5_1", "doi-asserted-by": "crossref", "first-page": "134", "DOI": "10.1186/s13058-015-0642-8", "article-title": "Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response", "volume": "17", "author": "Lips EH", "year": "2015", "journal-title": "Breast Cancer Res"}, {"key": "e_1_2_2_6_1", "doi-asserted-by": "crossref", "first-page": "346", "DOI": "10.1038/nature10983", "article-title": "The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups", "volume": "486", "author": "Curtis C", "year": "2012", "journal-title": "Nature"}, {"key": "e_1_2_2_7_1", "doi-asserted-by": "crossref", "first-page": "395", "DOI": "10.1038/nature10933", "article-title": "The clonal and mutational evolution spectrum of primary triple\u2010negative breast cancers", "volume": "486", "author": "Shah SP", "year": "2012", "journal-title": "Nature"}, {"key": "e_1_2_2_8_1", "doi-asserted-by": "crossref", "first-page": "25", "DOI": "10.1111/bjh.12075", "article-title": "Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations", "volume": "160", "author": "Bench AJ", "year": "2013", "journal-title": "Br J Haematol"}, {"key": "e_1_2_2_9_1", "doi-asserted-by": "crossref", "first-page": "e98", "DOI": "10.3324/haematol.2014.107656", "article-title": "Clinical and biological characterization of patients with low (0.1\u20102%) JAK2 V617F allele burden at diagnosis", "volume": "99", "author": "Lippert E", "year": "2014", "journal-title": "Haematologica"}, {"key": "e_1_2_2_10_1", "doi-asserted-by": "crossref", "first-page": "S27", "DOI": "10.1016/j.breast.2017.06.023", "article-title": "Mechanisms of resistance of chemotherapy in early\u2010stage triple negative breast cancer (TRBC)", "volume": "34", "author": "Wein L", "year": "2017", "journal-title": "Breast"}, {"key": "e_1_2_2_11_1", "doi-asserted-by": "crossref", "first-page": "169", "DOI": "10.1016/j.ccell.2017.07.005", "article-title": "Genomic evolution of breast cancer metastasis and relapse", "volume": "32", "author": "Yates LR", "year": "2017", "journal-title": "Cancer Cell"}], "container-title": ["The Breast Journal"], "language": "en", "link": [{"URL": "https://onlinelibrary.wiley.com/doi/pdf/10.1111/tbj.13683", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://onlinelibrary.wiley.com/doi/full-xml/10.1111/tbj.13683", "content-type": "application/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://onlinelibrary.wiley.com/doi/pdf/10.1111/tbj.13683", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 19]], "date-time": "2019-11-19T18:48:27Z", "timestamp": 1574189307000}, "score": 36.842457, "issued": {"date-parts": [[2019, 11, 19]]}, "references-count": 10, "alternative-id": ["10.1111/tbj.13683"], "URL": "http://dx.doi.org/10.1111/tbj.13683", "archive": ["Portico"], "relation": {"cites": []}, "ISSN": ["1075-122X", "1524-4741"], "issn-type": [{"value": "1075-122X", "type": "print"}, {"value": "1524-4741", "type": "electronic"}], "subject": ["Internal Medicine", "Surgery", "Oncology"], "assertion": [{"value": "2019-09-20", "order": 0, "name": "received", "label": "Received", "group": {"name": "publication_history", "label": "Publication History"}}, {"value": "2019-10-15", "order": 1, "name": "accepted", "label": "Accepted", "group": {"name": "publication_history", "label": "Publication History"}}, {"value": "2019-11-19", "order": 2, "name": "published", "label": "Published", "group": {"name": "publication_history", "label": "Publication History"}}], "article-number": "tbj.13683"}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T09:36:26Z", "timestamp": 1574501786174}, "reference-count": 33, "publisher": "Wiley", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2015, 9, 1]], "date-time": "2015-09-01T00:00:00Z", "timestamp": 1441065600000}, "delay-in-days": 1645, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2011, 3]]}, "DOI": "10.1111/j.1751-553x.2011.01308.x", "type": "journal-article", "created": {"date-parts": [[2011, 3, 25]], "date-time": "2011-03-25T06:58:48Z", "timestamp": 1301036328000}, "page": "no-no", "source": "Crossref", "is-referenced-by-count": 1, "title": ["Prevalence of overt myeloproliferative neoplasms and JAK2 V617F mutation in Korean patients with splanchnic vein thrombosis"], "prefix": "10.1111", "author": [{"given": "E.-H.", "family": "YOO", "sequence": "first", "affiliation": []}, {"given": "J.-H.", "family": "JANG", "sequence": "additional", "affiliation": []}, {"given": "K.-J.", "family": "PARK", "sequence": "additional", "affiliation": []}, {"given": "G.-Y.", "family": "GWAK", "sequence": "additional", "affiliation": []}, {"given": "H.-J.", "family": "KIM", "sequence": "additional", "affiliation": []}, {"given": "S.-H.", "family": "KIM", "sequence": "additional", "affiliation": []}, {"given": "D.-K.", "family": "KIM", "sequence": "additional", "affiliation": []}], "member": "311", "published-online": {"date-parts": [[2011, 3, 24]]}, "reference": [{"key": "10.1111/j.1751-553X.2011.01308.x-BIB1|cit1", "doi-asserted-by": "crossref", "first-page": "818", "DOI": "10.1007/BF01725198", "article-title": "Budd-Chiari syndrome and thrombosis of other abdominal vessels in the chronic myeloproliferative diseases", "volume": "67", "author": "Anger", "year": "1989", "journal-title": "Klin Wochenschr"}, {"key": "10.1111/j.1751-553X.2011.01308.x-BIB2|cit2", "doi-asserted-by": "crossref", "first-page": "307", "DOI": "10.1111/j.1365-2141.2008.07258.x", "article-title": "The JAK2 V617F mutation and thrombosis", "volume": "143", "author": "Austin", "year": "2008", "journal-title": "British Journal Haematology"}, {"key": "10.1111/j.1751-553X.2011.01308.x-BIB3|cit3", "doi-asserted-by": "crossref", "first-page": "547", "DOI": "10.1160/TH08-06-0396", "article-title": "Vascular events in Korean patients with myeloproliferative neoplasms and their relationship to JAK2 mutation", "volume": "101", "author": "Bang", "year": "2009", "journal-title": "Thrombosis and Haemostasis"}, {"key": "10.1111/j.1751-553X.2011.01308.x-BIB4|cit4", "doi-asserted-by": "crossref", "first-page": "381", "DOI": "10.1055/s-2006-942759", "article-title": "The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia", "volume": "32", "author": "Bellucci", "year": "2006", "journal-title": "Seminars in Thrombosis and Hemostasis"}, {"key": "10.1111/j.1751-553X.2011.01308.x-BIB5|cit5", "doi-asserted-by": "crossref", "first-page": "3223", "DOI": "10.1182/blood-2006-05-021527", "article-title": "Latent myeloproliferative disorder revealed by the JAK2-V617F mutation and endogenous megakaryocytic colonies in patients with splanchnic vein thrombosis", "volume": "108", "author": "Boissinot", "year": "2006", "journal-title": "Blood"}, {"key": "10.1111/j.1751-553X.2011.01308.x-BIB6|cit6", "doi-asserted-by": "crossref", "first-page": "208", "DOI": "10.1055/s-2006-939432", "article-title": "Budd-Chiari syndrome and portal vein thrombosis associated with myeloproliferative disorders: diagnosis and management", "volume": "32", "author": "Briere", "year": "2006", "journal-title": "Seminars in Thrombosis and Hemostasis"}, {"key": "10.1111/j.1751-553X.2011.01308.x-BIB7|cit7", "doi-asserted-by": "crossref", "first-page": "39", "DOI": "10.1007/s12185-008-0222-0", "article-title": "Comparison of clinicopathologic findings according to JAK2 V617F mutation in patients with essential thrombocythemia", "volume": "89", "author": "Cho", "year": "2009", "journal-title": "International Journal of Hematology"}, {"key": "10.1111/j.1751-553X.2011.01308.x-BIB8|cit8", "doi-asserted-by": "crossref", "first-page": "1430", "DOI": "10.1111/j.1538-7836.2008.03026.x", "article-title": "Inherited protein S deficiency as a result of a large duplication mutation of the PROS1 gene detected by multiplex ligation-dependent probe amplification", "volume": "6", "author": "Choung", "year": "2008", "journal-title": "Journal of Thrombosis and Haemostasis"}, {"key": "10.1111/j.1751-553X.2011.01308.x-BIB9|cit9", "doi-asserted-by": "crossref", "first-page": "55", "DOI": "10.1111/j.1538-7836.2006.02277.x", "article-title": "The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis", "volume": "5", "author": "Colaizzo", "year": "2007", "journal-title": "Journal of Thrombosis and Haemostasis"}, {"key": "10.1111/j.1751-553X.2011.01308.x-BIB10|cit10", "doi-asserted-by": "crossref", "first-page": "708", "DOI": "10.1111/j.1538-7836.2007.02424.x", "article-title": "Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders", "volume": "5", "author": "De Stefano", "year": "2007", "journal-title": "Journal of Thrombosis and Haemostasis"}, {"key": "10.1111/j.1751-553X.2011.01308.x-BIB11|cit11", "doi-asserted-by": "crossref", "first-page": "141", "DOI": "10.1007/s00277-009-0788-5", "article-title": "Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation", "volume": "89", "author": "De Stefano", "year": "2010", "journal-title": "Annals of Hematology"}, {"key": "10.1111/j.1751-553X.2011.01308.x-BIB12|cit12", "doi-asserted-by": "crossref", "first-page": "587", "DOI": "10.1002/hep.510310307", "article-title": "Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors", "volume": "31", "author": "Denninger", "year": "2000", "journal-title": "Hepatology"}, {"key": "10.1111/j.1751-553X.2011.01308.x-BIB13|cit13", "doi-asserted-by": "crossref", "first-page": "5617", "DOI": "10.1182/blood-2008-12-196014", "article-title": "JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis", "volume": "113", "author": "Dentali", "year": "2009", "journal-title": "Blood"}, {"key": "10.1111/j.1751-553X.2011.01308.x-BIB14|cit14", "doi-asserted-by": "crossref", "first-page": "126", "DOI": "10.1002/ajh.21335", "article-title": "Absence of the JAK2 exon 12 mutations in patients with splanchnic venous thrombosis and without overt myeloproliferative neoplasms", "volume": "84", "author": "Fiorini", "year": "2009", "journal-title": "American Journal of Hematology"}, {"key": "10.1111/j.1751-553X.2011.01308.x-BIB15|cit15", "doi-asserted-by": "crossref", "first-page": "656", "DOI": "10.7326/0003-4819-123-9-199511010-00003", "article-title": "Polycythemia vera: the natural history of 1213 patients followed for 20\u2003years", "volume": "123", "author": "Gruppo Italiano Studio Policitemia", "year": "1995", "journal-title": "Annals of Internal Medicine"}, {"key": "10.1111/j.1751-553X.2011.01308.x-BIB16|cit16", "doi-asserted-by": "crossref", "first-page": "1144", "DOI": "10.1038/nature03546", "article-title": "A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera", "volume": "434", "author": "James", "year": "2005", "journal-title": "Nature"}, {"key": "10.1111/j.1751-553X.2011.01308.x-BIB17|cit17", "doi-asserted-by": "crossref", "first-page": "4922", "DOI": "10.1182/blood-2007-11-125328", "article-title": "The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis:a report on 241 cases", "volume": "111", "author": "Kiladjian", "year": "2008", "journal-title": "Blood"}, {"key": "10.1111/j.1751-553X.2011.01308.x-BIB18|cit18", "first-page": "181", "article-title": "Absence of factor V Leiden mutation in Koreans", "volume": "86", "author": "Kim", "year": "1997", "journal-title": "Thrombosis Research"}, {"key": "10.1111/j.1751-553X.2011.01308.x-BIB19|cit19", "doi-asserted-by": "crossref", "first-page": "587", "DOI": "10.3346/jkms.1998.13.6.587", "article-title": "Low prevalence of activated protein C resistance and coagulation factor V Arg506 to Gln mutation among Korean patients with deep vein thrombosis", "volume": "13", "author": "Kim", "year": "1998", "journal-title": "Journal of Korean Medical Science"}, {"key": "10.1111/j.1751-553X.2011.01308.x-BIB20|cit20", "doi-asserted-by": "crossref", "first-page": "1779", "DOI": "10.1056/NEJMoa051113", "article-title": "A gain-of-function mutation of JAK2 in myeloproliferative disorders", "volume": "352", "author": "Kralovics", "year": "2005", "journal-title": "New England Journal of Medicine"}, {"key": "10.1111/j.1751-553X.2011.01308.x-BIB21|cit21", "doi-asserted-by": "crossref", "first-page": "701", "DOI": "10.1111/j.1538-7836.2008.02905.x", "article-title": "Detection of large deletion mutations in the SERPINC1 gene causing hereditary antithrombin deficiency by multiplex ligation-dependent probe amplification (MLPA)", "volume": "6", "author": "Lee", "year": "2008", "journal-title": "Journal of Thrombosis and Haemostasis"}, {"key": "10.1111/j.1751-553X.2011.01308.x-BIB22|cit22", "doi-asserted-by": "crossref", "first-page": "736", "DOI": "10.1309/JA1WD8JNVLGYNQYE", "article-title": "JAK2 V617F mutation in patients with catastrophic intra-abdominal thromboses", "volume": "127", "author": "McMahon", "year": "2007", "journal-title": "American Journal of Clinical Pathology"}, {"key": "10.1111/j.1751-553X.2011.01308.x-BIB23|cit23", "doi-asserted-by": "crossref", "first-page": "2031", "DOI": "10.1053/j.gastro.2006.04.008", "article-title": "Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome", "volume": "130", "author": "Patel", "year": "2006", "journal-title": "Gastroenterology"}, {"key": "10.1111/j.1751-553X.2011.01308.x-BIB24|cit24", "doi-asserted-by": "crossref", "first-page": "293", "DOI": "10.1055/s-0028-1085097", "article-title": "The role of thrombophilia in splanchnic vein thrombosis", "volume": "28", "author": "Primignani", "year": "2008", "journal-title": "Seminars in Liver Disease"}, {"key": "10.1111/j.1751-553X.2011.01308.x-BIB25|cit25", "doi-asserted-by": "crossref", "first-page": "1528", "DOI": "10.1002/hep.21435", "article-title": "Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis", "volume": "44", "author": "Primignani", "year": "2006", "journal-title": "Hepatology"}, {"key": "10.1111/j.1751-553X.2011.01308.x-BIB26|cit26", "doi-asserted-by": "crossref", "first-page": "859", "DOI": "10.1111/j.1538-7836.2007.02384.x", "article-title": "JAK2 V617F is specifically associated with idiopathic splanchnic vein thrombosis", "volume": "5", "author": "Regina", "year": "2007", "journal-title": "Journal of Thrombosis and Haemostasis"}, {"key": "10.1111/j.1751-553X.2011.01308.x-BIB27|cit27", "doi-asserted-by": "crossref", "first-page": "990", "DOI": "10.1055/s-0037-1614612", "article-title": "Absence of the prothrombin gene variant in Koreans", "volume": "81", "author": "Song", "year": "1999", "journal-title": "Thrombosis and Haemostasis"}, {"key": "10.1111/j.1751-553X.2011.01308.x-BIB28|cit28", "doi-asserted-by": "crossref", "first-page": "14", "DOI": "10.1038/sj.leu.2404955", "article-title": "Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms", "volume": "22", "author": "Tefferi", "year": "2008", "journal-title": "Leukemia"}, {"key": "10.1111/j.1751-553X.2011.01308.x-BIB29|cit29", "doi-asserted-by": "crossref", "first-page": "1092", "DOI": "10.1182/blood-2007-04-083501", "article-title": "Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel", "volume": "110", "author": "Tefferi", "year": "2007", "journal-title": "Blood"}, {"key": "10.1111/j.1751-553X.2011.01308.x-BIB30|cit30", "doi-asserted-by": "crossref", "first-page": "S204", "DOI": "10.1111/j.1440-1746.2004.03642.x", "article-title": "Hepatic venous outflow tract obstruction etiopathogenesis: Asia versus the West", "volume": "19", "author": "Valla", "year": "2004", "journal-title": "Journal of Gastroenterology and Hepatology"}, {"key": "10.1111/j.1751-553X.2011.01308.x-BIB31|cit31", "doi-asserted-by": "crossref", "first-page": "329", "DOI": "10.7326/0003-4819-103-3-329", "article-title": "Primary myeloproliferative disorder and hepatic vein thrombosis. A prospective study of erythroid colony formation in vitro in 20 patients with Budd-Chiari syndrome", "volume": "103", "author": "Valla", "year": "1985", "journal-title": "Annals of Internal Medicine"}, {"key": "10.1111/j.1751-553X.2011.01308.x-BIB32|cit32", "doi-asserted-by": "crossref", "first-page": "S11", "DOI": "10.1016/S0049-3848(09)70136-7", "article-title": "Effects of race and ethnicity on the incidence of venous thromboembolism", "volume": "123", "author": "White", "year": "2009", "journal-title": "Thrombosis Research"}, {"key": "10.1111/j.1751-553X.2011.01308.x-BIB33|cit33", "doi-asserted-by": "crossref", "first-page": "1770", "DOI": "10.1007/s10620-009-0933-y", "article-title": "JAK2V617F mutation in patients with splanchnic vein thrombosis", "volume": "55", "author": "Xavier", "year": "2010", "journal-title": "Digestive Diseases and Sciences"}], "container-title": ["International Journal of Laboratory Hematology"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1751-553X.2011.01308.x", "content-type": "unspecified", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 6, 9]], "date-time": "2019-06-09T12:21:54Z", "timestamp": 1560082914000}, "score": 36.4279, "subtitle": ["THE JAK2 V617F MUTATION IN KOREAN PATIENTS WITH SVT"], "issued": {"date-parts": [[2011, 3]]}, "references-count": 33, "URL": "http://dx.doi.org/10.1111/j.1751-553x.2011.01308.x", "relation": {"cites": []}, "ISSN": ["1751-5521"], "issn-type": [{"value": "1751-5521", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 20]], "date-time": "2019-11-20T11:32:14Z", "timestamp": 1574249534688}, "reference-count": 35, "publisher": "Wiley", "issue": "1", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2015, 9, 1]], "date-time": "2015-09-01T00:00:00Z", "timestamp": 1441065600000}, "delay-in-days": 3238, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2007, 1]]}, "DOI": "10.1111/j.1538-7836.2006.02277.x", "type": "journal-article", "created": {"date-parts": [[2006, 12, 12]], "date-time": "2006-12-12T23:57:45Z", "timestamp": 1165967865000}, "page": "55-61", "source": "Crossref", "is-referenced-by-count": 102, "title": ["The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis"], "prefix": "10.1111", "volume": "5", "author": [{"given": "D.", "family": "COLAIZZO", "sequence": "first", "affiliation": []}, {"given": "L.", "family": "AMITRANO", "sequence": "additional", "affiliation": []}, {"given": "G. L.", "family": "TISCIA", "sequence": "additional", "affiliation": []}, {"given": "G.", "family": "SCENNA", "sequence": "additional", "affiliation": []}, {"given": "E.", "family": "GRANDONE", "sequence": "additional", "affiliation": []}, {"given": "M. A.", "family": "GUARDASCIONE", "sequence": "additional", "affiliation": []}, {"given": "V.", "family": "BRANCACCIO", "sequence": "additional", "affiliation": []}, {"given": "M.", "family": "MARGAGLIONE", "sequence": "additional", "affiliation": []}], "member": "311", "published-online": {"date-parts": [[2006, 10, 20]]}, "reference": [{"key": "10.1111/j.1538-7836.2006.02277.x-BIB1|cit1", "doi-asserted-by": "crossref", "first-page": "861", "DOI": "10.1001/archinte.154.8.861", "article-title": "The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly", "volume": "154", "author": "Kniffin", "year": "1994", "journal-title": "Arch Intern Med"}, {"key": "10.1111/j.1538-7836.2006.02277.x-BIB2|cit2", "first-page": "3531", "article-title": "Inherited thrombophilia. Pathogenesis, clinical syndromes and management", "volume": "87", "author": "De Stefano", "year": "1996", "journal-title": "Blood"}, {"key": "10.1111/j.1538-7836.2006.02277.x-BIB3|cit3", "doi-asserted-by": "crossref", "first-page": "587", "DOI": "10.1002/hep.510310307", "article-title": "Cause of portal or hepatic vein thrombosis in adults: the role of multiple concurrent factors", "volume": "31", "author": "Denninger", "year": "2000", "journal-title": "Hepatology"}, {"key": "10.1111/j.1538-7836.2006.02277.x-BIB4|cit4", "first-page": "656", "article-title": "Polycythemia vera: the natural history of 1,213 patients followed for 20\u2003years", "volume": "123", "author": "Gruppo Italiano Studio Policitemia", "year": "1995", "journal-title": "Ann Intern Med"}, {"key": "10.1111/j.1538-7836.2006.02277.x-BIB5|cit5", "doi-asserted-by": "crossref", "first-page": "31", "DOI": "10.1177/107602960000600105", "article-title": "Essential thrombocythemia in young adults: major thrombotic complications and complications during pregnancy - a follow up study of 68 patients", "volume": "6", "author": "Randi", "year": "2000", "journal-title": "Clin Appl Thromb Hemost"}, {"key": "10.1111/j.1538-7836.2006.02277.x-BIB6|cit6", "doi-asserted-by": "crossref", "first-page": "10", "DOI": "10.1053/j.seminhematol.2004.02.008", "article-title": "Propensity for hemorrhage and thrombosis in chronic myeloproliferative disorders", "volume": "41", "author": "Kessler", "year": "2004", "journal-title": "Semin Hematol"}, {"key": "10.1111/j.1538-7836.2006.02277.x-BIB7|cit7", "doi-asserted-by": "crossref", "first-page": "312", "DOI": "10.1007/s002779900136", "article-title": "Myeloproliferative disorders: complications, survival and causes of death", "volume": "79", "author": "Brodmann", "year": "2000", "journal-title": "Ann Hematol"}, {"key": "10.1111/j.1538-7836.2006.02277.x-BIB8|cit8", "doi-asserted-by": "crossref", "first-page": "411", "DOI": "10.1055/s-2007-996117", "article-title": "Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis", "volume": "23", "author": "De Stefano", "year": "1997", "journal-title": "Semin Thromb Hemost"}, {"key": "10.1111/j.1538-7836.2006.02277.x-BIB9|cit9", "doi-asserted-by": "crossref", "first-page": "755", "DOI": "10.1016/j.amjmed.2004.06.032", "article-title": "Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia", "volume": "117", "author": "Passamonti", "year": "2004", "journal-title": "Am J Med"}, {"key": "10.1111/j.1538-7836.2006.02277.x-BIB10|cit10", "doi-asserted-by": "crossref", "first-page": "1054", "DOI": "10.1016/S0140-6736(05)71142-9", "article-title": "Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders", "volume": "365", "author": "Baxter", "year": "2005", "journal-title": "Lancet"}, {"key": "10.1111/j.1538-7836.2006.02277.x-BIB11|cit11", "doi-asserted-by": "crossref", "first-page": "1144", "DOI": "10.1038/nature03546", "article-title": "A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera", "volume": "434", "author": "James", "year": "2005", "journal-title": "Nature"}, {"key": "10.1111/j.1538-7836.2006.02277.x-BIB12|cit12", "doi-asserted-by": "crossref", "first-page": "3374", "DOI": "10.1182/blood-2005-05-1889", "article-title": "Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2", "volume": "106", "author": "Kralovics", "year": "2005", "journal-title": "Blood"}, {"key": "10.1111/j.1538-7836.2006.02277.x-BIB13|cit13", "doi-asserted-by": "crossref", "first-page": "3377", "DOI": "10.1182/blood-2005-05-1898", "article-title": "The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia", "volume": "106", "author": "Levine", "year": "2005", "journal-title": "Blood"}, {"key": "10.1111/j.1538-7836.2006.02277.x-BIB14|cit14", "doi-asserted-by": "crossref", "first-page": "387", "DOI": "10.1016/j.ccr.2005.03.023", "article-title": "Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis", "volume": "7", "author": "Levine", "year": "2005", "journal-title": "Cancer Cell"}, {"key": "10.1111/j.1538-7836.2006.02277.x-BIB15|cit15", "doi-asserted-by": "crossref", "first-page": "1779", "DOI": "10.1056/NEJMoa051113", "article-title": "A gain-of-function mutation of JAK2 in myeloproliferative disorders", "volume": "352", "author": "Kralovics", "year": "2005", "journal-title": "N Engl J Med"}, {"key": "10.1111/j.1538-7836.2006.02277.x-BIB16|cit16", "doi-asserted-by": "crossref", "first-page": "2031", "DOI": "10.1053/j.gastro.2006.04.008", "article-title": "Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome", "volume": "130", "author": "Patel", "year": "2006", "journal-title": "Gastroenterology"}, {"key": "10.1111/j.1538-7836.2006.02277.x-BIB17|cit17", "doi-asserted-by": "crossref", "first-page": "1591", "DOI": "10.1182/blood-2002-06-1843", "article-title": "Mutations in the VHL gene in sporadic apparently congenital polycythemia", "volume": "101", "author": "Pastore", "year": "2003", "journal-title": "Blood"}, {"key": "10.1111/j.1538-7836.2006.02277.x-BIB18|cit18", "doi-asserted-by": "crossref", "first-page": "3924", "DOI": "10.1182/blood-2003-07-2535", "article-title": "Congenital disorder of oxygensensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors", "volume": "103", "author": "Gordeuk", "year": "2004", "journal-title": "Blood"}, {"key": "10.1111/j.1538-7836.2006.02277.x-BIB19|cit19", "first-page": "128", "article-title": "Congenital polycythemia with homozygous and heterozygous mutations of von Hippel-Lindau gene: five new Caucasian patients", "volume": "90", "author": "Bento", "year": "2005", "journal-title": "Haematologica"}, {"key": "10.1111/j.1538-7836.2006.02277.x-BIB20|cit20", "author": "Pierre", "first-page": "32", "year": "2001", "volume-title": "The World Health Organization Classification of Tumors"}, {"key": "10.1111/j.1538-7836.2006.02277.x-BIB21|cit21", "first-page": "907", "article-title": "The Methylenetetrahydrofolate reductase TT677 genotype is associated with venous thrombosis independently of the coexistence of the FV Leiden and the prothrombin A20210 mutations", "volume": "79", "author": "Margaglione", "year": "1998", "journal-title": "Thromb Haemost"}, {"key": "10.1111/j.1538-7836.2006.02277.x-BIB22|cit22", "doi-asserted-by": "crossref", "first-page": "89", "DOI": "10.7326/0003-4819-129-2-199807150-00003", "article-title": "Increased risk of venous thrombosis in carriers of the prothrombin A20210 gene variant", "volume": "129", "author": "Margaglione", "year": "1998", "journal-title": "Ann Intern Med"}, {"key": "10.1111/j.1538-7836.2006.02277.x-BIB23|cit23", "first-page": "1031", "article-title": "Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families", "volume": "84", "author": "Koeleman", "year": "1994", "journal-title": "Blood"}, {"key": "10.1111/j.1538-7836.2006.02277.x-BIB24|cit24", "first-page": "3698", "article-title": "A common genetic variation in the 3\u2032-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis", "volume": "88", "author": "Poort", "year": "1996", "journal-title": "Blood"}, {"key": "10.1111/j.1538-7836.2006.02277.x-BIB25|cit25", "doi-asserted-by": "crossref", "first-page": "1945", "DOI": "10.1016/S0140-6736(05)67785-9", "article-title": "Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study", "volume": "366", "author": "Campbell", "year": "2005", "journal-title": "Lancet"}, {"key": "10.1111/j.1538-7836.2006.02277.x-BIB26|cit26", "doi-asserted-by": "crossref", "first-page": "720", "DOI": "10.1136/gut.49.5.720", "article-title": "Extrahepatic portal vein thrombosis: aetiology and determinants of survival", "volume": "49", "author": "Janssen", "year": "2001", "journal-title": "Gut"}, {"key": "10.1111/j.1538-7836.2006.02277.x-BIB27|cit27", "doi-asserted-by": "crossref", "first-page": "535", "DOI": "10.1111/j.1572-0241.2002.05527.x", "article-title": "Portal vein thrombosis: a concise review", "volume": "97", "author": "Sobhonslidsuk", "year": "2002", "journal-title": "Am J Gastroenterol"}, {"key": "10.1111/j.1538-7836.2006.02277.x-BIB28|cit28", "doi-asserted-by": "crossref", "first-page": "345", "DOI": "10.1002/hep.510310213", "article-title": "Inherited coagulation disorders in cirrhotic patients with portal vein thrombosis", "volume": "31", "author": "Amitrano", "year": "2000", "journal-title": "Hepatology"}, {"key": "10.1111/j.1538-7836.2006.02277.x-BIB29|cit29", "first-page": "2364", "article-title": "Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study", "volume": "96", "author": "Janssen", "year": "2000", "journal-title": "Blood"}, {"key": "10.1111/j.1538-7836.2006.02277.x-BIB30|cit30", "doi-asserted-by": "crossref", "first-page": "1167", "DOI": "10.1016/S0140-6736(98)10266-0", "article-title": "Venous thrombosis: a multicausal disease", "volume": "353", "author": "Rosendaal", "year": "1999", "journal-title": "Lancet"}, {"key": "10.1111/j.1538-7836.2006.02277.x-BIB31|cit31", "doi-asserted-by": "crossref", "first-page": "4272", "DOI": "10.1182/blood-2001-12-0349", "article-title": "Polycythemia vera: myths, mechanisms, and management", "volume": "100", "author": "Spivak", "year": "2002", "journal-title": "Blood"}, {"key": "10.1111/j.1538-7836.2006.02277.x-BIB32|cit32", "doi-asserted-by": "crossref", "first-page": "796", "DOI": "10.1046/j.1365-2141.2002.03474.x", "article-title": "Current trends in essential thrombocythaemia", "volume": "117", "author": "Harrison", "year": "2002", "journal-title": "Br J Haematol"}, {"key": "10.1111/j.1538-7836.2006.02277.x-BIB33|cit33", "doi-asserted-by": "crossref", "first-page": "739", "DOI": "10.1016/j.leukres.2006.01.004", "article-title": "Mutation screening for JAK2V617F: when to order the test and how to interpret the results", "volume": "30", "author": "Tefferi", "year": "2006", "journal-title": "Leuk Res"}, {"key": "10.1111/j.1538-7836.2006.02277.x-BIB34|cit34", "doi-asserted-by": "crossref", "first-page": "18962", "DOI": "10.1073/pnas.0509714102", "article-title": "Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation", "volume": "102", "author": "Lu", "year": "2005", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "10.1111/j.1538-7836.2006.02277.x-BIB35|cit35", "doi-asserted-by": "crossref", "first-page": "514", "DOI": "10.1182/blood-2005-06-2422", "article-title": "Von Hippel-Lindau-dependent polycythemia is endemic on the island of Ischia: identification of a novel cluster", "volume": "107", "author": "Perrotta", "year": "2006", "journal-title": "Blood"}], "container-title": ["Journal of Thrombosis and Haemostasis"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1538-7836.2006.02277.x", "content-type": "unspecified", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2017, 6, 17]], "date-time": "2017-06-17T12:01:31Z", "timestamp": 1497700891000}, "score": 35.263878, "subtitle": ["JAK2 V617F mutation and occurrence of PMVT"], "issued": {"date-parts": [[2006, 10, 20]]}, "references-count": 35, "journal-issue": {"published-print": {"date-parts": [[2007, 1]]}, "issue": "1"}, "URL": "http://dx.doi.org/10.1111/j.1538-7836.2006.02277.x", "relation": {"cites": []}, "ISSN": ["1538-7933"], "issn-type": [{"value": "1538-7933", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 22]], "date-time": "2019-11-22T23:41:06Z", "timestamp": 1574466066216}, "reference-count": 31, "publisher": "Wiley", "issue": "6", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2015, 9, 1]], "date-time": "2015-09-01T00:00:00Z", "timestamp": 1441065600000}, "delay-in-days": 1188, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2012, 6]]}, "DOI": "10.1111/j.1538-7836.2012.04719.x", "type": "journal-article", "created": {"date-parts": [[2012, 4, 3]], "date-time": "2012-04-03T17:00:01Z", "timestamp": 1333472401000}, "page": "998-1003", "source": "Crossref", "is-referenced-by-count": 29, "title": ["The JAK2\u00a0V617F mutation in patients with cerebral venous thrombosis"], "prefix": "10.1111", "volume": "10", "author": [{"given": "S. M.", "family": "PASSAMONTI", "sequence": "first", "affiliation": []}, {"given": "E.", "family": "BIGUZZI", "sequence": "additional", "affiliation": []}, {"given": "M.", "family": "CAZZOLA", "sequence": "additional", "affiliation": []}, {"given": "F.", "family": "FRANCHI", "sequence": "additional", "affiliation": []}, {"given": "F.", "family": "GIANNIELLO", "sequence": "additional", "affiliation": []}, {"given": "P.", "family": "BUCCIARELLI", "sequence": "additional", "affiliation": []}, {"given": "D.", "family": "PIETRA", "sequence": "additional", "affiliation": []}, {"given": "P. M.", "family": "MANNUCCI", "sequence": "additional", "affiliation": []}, {"given": "I.", "family": "MARTINELLI", "sequence": "additional", "affiliation": []}], "member": "311", "published-online": {"date-parts": [[2012, 5, 31]]}, "reference": [{"key": "10.1111/j.1538-7836.2012.04719.x-BIB1|cit1", "doi-asserted-by": "crossref", "first-page": "2452", "DOI": "10.1056/NEJMra063728", "article-title": "The myeloprolifertaive disorders", "volume": "355", "author": "Campbell", "year": "2006", "journal-title": "N Engl J Med"}, {"key": "10.1111/j.1538-7836.2012.04719.x-BIB2|cit2", "doi-asserted-by": "crossref", "first-page": "818", "DOI": "10.1007/BF01725198", "article-title": "Budd-Chiari syndrome and thrombosis of other abdominal vessels in the chronic myeloproliferative diseases", "volume": "67", "author": "Anger", "year": "1989", "journal-title": "Klin Wochenschr"}, {"key": "10.1111/j.1538-7836.2012.04719.x-BIB3|cit3", "doi-asserted-by": "crossref", "first-page": "539", "DOI": "10.1007/s002770050555", "article-title": "Thrombosis-free survival and life expectancy in 187 consecutive patients with essential thrombocytemia", "volume": "78", "author": "Bazzan", "year": "1999", "journal-title": "Ann Haematol"}, {"key": "10.1111/j.1538-7836.2012.04719.x-BIB4|cit4", "doi-asserted-by": "crossref", "first-page": "307", "DOI": "10.1111/j.1365-2141.2008.07258.x", "article-title": "The JAK2\u00a0V617F mutation and thrombosis", "volume": "143", "author": "Austin", "year": "2008", "journal-title": "Br J Haematol"}, {"key": "10.1111/j.1538-7836.2012.04719.x-BIB5|cit5", "doi-asserted-by": "crossref", "first-page": "1779", "DOI": "10.1056/NEJMoa051113", "article-title": "A gain of function mutation of JAK2 in myeloproliferative disorders", "volume": "352", "author": "Kralovics", "year": "2005", "journal-title": "N Engl J Med"}, {"key": "10.1111/j.1538-7836.2012.04719.x-BIB6|cit6", "doi-asserted-by": "crossref", "first-page": "14", "DOI": "10.1038/sj.leu.2404955", "article-title": "Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms", "volume": "22", "author": "Tefferi", "year": "2008", "journal-title": "Leukemia"}, {"key": "10.1111/j.1538-7836.2012.04719.x-BIB7|cit7", "doi-asserted-by": "crossref", "first-page": "171", "DOI": "10.3322/caac.20009", "article-title": "Advances in understanding and management of myelopoliferative neoplasms", "volume": "59", "author": "Vannucchi", "year": "2009", "journal-title": "CA Cancer J Clin"}, {"key": "10.1111/j.1538-7836.2012.04719.x-BIB8|cit8", "doi-asserted-by": "crossref", "first-page": "708", "DOI": "10.1111/j.1538-7836.2007.02424.x", "article-title": "Incidence of the JAK2\u00a0V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders", "volume": "5", "author": "De Stefano", "year": "2007", "journal-title": "J Thromb Haemost"}, {"key": "10.1111/j.1538-7836.2012.04719.x-BIB9|cit9", "doi-asserted-by": "crossref", "first-page": "412", "DOI": "10.1136/jmg.2006.048371", "article-title": "Gain-of-function gene mutations and venous thromboembolism: distinct roles in different clinical settings", "volume": "44", "author": "Colaizzo", "year": "2007", "journal-title": "J Med Genet"}, {"key": "10.1111/j.1538-7836.2012.04719.x-BIB10|cit10", "doi-asserted-by": "crossref", "first-page": "1119", "DOI": "10.1160/TH08-02-0081", "article-title": "The V617F\u00a0JAK2 mutation is not a frequent event in patients with cerebral venous thrombosis without overt chronic myeloproliferative disorders", "volume": "99", "author": "Bellucci", "year": "2008", "journal-title": "Thromb Haemost"}, {"key": "10.1111/j.1538-7836.2012.04719.x-BIB11|cit11", "doi-asserted-by": "crossref", "first-page": "1121", "DOI": "10.1160/TH08-04-0205", "article-title": "The JAK2\u00a0V617F mutation in patients with cerebral venous thrombosis: a rebuttal", "volume": "99", "author": "De Stefano", "year": "2008", "journal-title": "Thromb Haemost"}, {"key": "10.1111/j.1538-7836.2012.04719.x-BIB12|cit12", "doi-asserted-by": "crossref", "first-page": "468", "DOI": "10.1097/MBC.0b013e328304e0a9", "article-title": "Low prevalence of the JAK2V617F in patients with ischemic stroke or cerebral venous thrombosis", "volume": "19", "author": "Xavier", "year": "2008", "journal-title": "Blood Coagul Fibrinol"}, {"key": "10.1111/j.1538-7836.2012.04719.x-BIB13|cit13", "doi-asserted-by": "crossref", "first-page": "1039", "DOI": "10.1111/j.1538-7836.2009.03354.x", "article-title": "JAK2-V617F mutation in cerebral venous thrombosis", "volume": "7", "author": "Koopman", "year": "2009", "journal-title": "J Thromb Haemost"}, {"key": "10.1111/j.1538-7836.2012.04719.x-BIB14|cit14", "doi-asserted-by": "crossref", "first-page": "5617", "DOI": "10.1182/blood-2008-12-196014", "article-title": "JAK2\u00a0V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis", "volume": "113", "author": "Dentali", "year": "2009", "journal-title": "Blood"}, {"key": "10.1111/j.1538-7836.2012.04719.x-BIB15|cit15", "doi-asserted-by": "crossref", "first-page": "117", "DOI": "10.1111/j.1751-553X.2010.01275.x", "article-title": "JAK2\u00a0F617F mutation in patients with thrombosis: to screen or not to screen?", "volume": "33", "author": "Xavier", "year": "2011", "journal-title": "Int J Lab Hematol"}, {"key": "10.1111/j.1538-7836.2012.04719.x-BIB16|cit16", "doi-asserted-by": "crossref", "first-page": "W163", "DOI": "10.7326/0003-4819-147-8-200710160-00010-w1", "article-title": "Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration", "volume": "147", "author": "Vandenbroucke", "year": "2007", "journal-title": "Ann Intern Med"}, {"key": "10.1111/j.1538-7836.2012.04719.x-BIB17|cit17", "doi-asserted-by": "crossref", "first-page": "64", "DOI": "10.1038/369064a0", "article-title": "Mutation in blood coagulation factor\u00a0V associated with resistance to activated protein\u00a0C", "volume": "369", "author": "Bertina", "year": "1994", "journal-title": "Nature"}, {"key": "10.1111/j.1538-7836.2012.04719.x-BIB18|cit18", "first-page": "3698", "article-title": "A common genetic variation in the 3\u2032-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis", "volume": "88", "author": "Poort", "year": "1996", "journal-title": "Blood"}, {"key": "10.1111/j.1538-7836.2012.04719.x-BIB19|cit19", "doi-asserted-by": "crossref", "first-page": "25", "DOI": "10.1055/s-2005-863802", "article-title": "Review of the clinical and diagnostic utility of laboratory tests for the detection of congenital thrombophilia", "volume": "31", "author": "Tripodi", "year": "2005", "journal-title": "Semin Thromb Haemost"}, {"key": "10.1111/j.1538-7836.2012.04719.x-BIB20|cit20", "doi-asserted-by": "crossref", "first-page": "1737", "DOI": "10.1111/j.1538-7836.2009.03555.x", "article-title": "Update of the guidelines for lupus anticoagulant detection", "volume": "7", "author": "Pengo", "year": "2009", "journal-title": "J Thromb Haemost"}, {"key": "10.1111/j.1538-7836.2012.04719.x-BIB21|cit21", "doi-asserted-by": "crossref", "first-page": "279", "DOI": "10.1016/S0049-3848(97)00013-3", "article-title": "Absence of hyperhomocysteinemia in ten patients with primary pulmonary hypertension", "volume": "85", "author": "Zighetti", "year": "1997", "journal-title": "Thromb Res"}, {"key": "10.1111/j.1538-7836.2012.04719.x-BIB22|cit22", "doi-asserted-by": "crossref", "first-page": "3676", "DOI": "10.1182/blood-2005-09-3826", "article-title": "Relation between JAK2\u00a0(V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders", "volume": "107", "author": "Passamonti", "year": "2006", "journal-title": "Blood"}, {"key": "10.1111/j.1538-7836.2012.04719.x-BIB23|cit23", "doi-asserted-by": "crossref", "first-page": "1574", "DOI": "10.1038/leu.2010.148", "article-title": "A prospective study of 338 patients with polycythemia vera: the impact of JAK2\u00a0(V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications", "volume": "24", "author": "Passamonti", "year": "2010", "journal-title": "Leukemia"}, {"key": "10.1111/j.1538-7836.2012.04719.x-BIB24|cit24", "doi-asserted-by": "crossref", "first-page": "2813", "DOI": "10.1182/blood-2010-11-316810", "article-title": "Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon\u00a012 mutations", "volume": "117", "author": "Passamonti", "year": "2011", "journal-title": "Blood"}, {"key": "10.1111/j.1538-7836.2012.04719.x-BIB25|cit25", "doi-asserted-by": "crossref", "first-page": "1484", "DOI": "10.3324/haematol.2009.013375", "article-title": "Blood cell activation in myeloproliferative neoplasms", "volume": "94", "author": "Cervantes", "year": "2009", "journal-title": "Haematologica"}, {"key": "10.1111/j.1538-7836.2012.04719.x-BIB26|cit26", "doi-asserted-by": "crossref", "first-page": "702", "DOI": "10.1016/j.exphem.2007.01.053", "article-title": "V617F\u00a0JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecule", "volume": "35", "author": "Falanga", "year": "2007", "journal-title": "Exp Hematol"}, {"key": "10.1111/j.1538-7836.2012.04719.x-BIB27|cit27", "doi-asserted-by": "crossref", "first-page": "372", "DOI": "10.3324/haematol.12053", "article-title": "Recurrent thrombosis in patients with polycytemia vera and essential thrombocytemia: incidence, risk factors, and effect of treatments", "volume": "93", "author": "De Stefano", "year": "2008", "journal-title": "Haematologica"}, {"key": "10.1111/j.1538-7836.2012.04719.x-BIB28|cit28", "doi-asserted-by": "crossref", "first-page": "1229", "DOI": "10.1111/j.1468-1331.2010.03011.x", "article-title": "EFNS guideline on the treatment of cerebral venous and sinus thrombosis in adult patients", "volume": "17", "author": "Einh\u00e4upl", "year": "2010", "journal-title": "Eur J Neurol"}, {"key": "10.1111/j.1538-7836.2012.04719.x-BIB29|cit29", "doi-asserted-by": "crossref", "first-page": "2740", "DOI": "10.1161/CIRCULATIONAHA.109.927046", "article-title": "Long-term evaluation of the risk of recurrence after cerebral sinus-venous thrombosis", "volume": "121", "author": "Martinelli", "year": "2010", "journal-title": "Circulation"}, {"key": "10.1111/j.1538-7836.2012.04719.x-BIB30|cit30", "doi-asserted-by": "crossref", "first-page": "454S", "DOI": "10.1378/chest.08-0658", "article-title": "Antithrombotic therapy for venous thromboembolic disease. ACCP evidence-based clinical practice guidelines (8th edition)", "volume": "133", "author": "Kearon", "year": "2008", "journal-title": "Chest"}, {"key": "10.1111/j.1538-7836.2012.04719.x-BIB31|cit31", "doi-asserted-by": "crossref", "first-page": "1180", "DOI": "10.1056/NEJMe1005856", "article-title": "From palliation to targeted therapy in myelofibrosis", "volume": "363", "author": "Vannucchi", "year": "2010", "journal-title": "N Engl J Med"}], "container-title": ["Journal of Thrombosis and Haemostasis"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1538-7836.2012.04719.x", "content-type": "unspecified", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 6, 26]], "date-time": "2019-06-26T17:49:39Z", "timestamp": 1561571379000}, "score": 35.263878, "subtitle": ["JAK2\u00a0V617F mutation and cerebral venous thrombosis"], "issued": {"date-parts": [[2012, 5, 31]]}, "references-count": 31, "journal-issue": {"published-print": {"date-parts": [[2012, 6]]}, "issue": "6"}, "URL": "http://dx.doi.org/10.1111/j.1538-7836.2012.04719.x", "relation": {"cites": []}, "ISSN": ["1538-7933"], "issn-type": [{"value": "1538-7933", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 25]], "date-time": "2019-11-25T18:34:41Z", "timestamp": 1574706881086}, "reference-count": 4, "publisher": "Elsevier BV", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2017, 1, 1]], "date-time": "2017-01-01T00:00:00Z", "timestamp": 1483228800000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": ["ejinme.com", "clinicalkey.jp", "clinicalkey.com", "clinicalkey.es", "clinicalkey.com.au", "clinicalkey.fr", "elsevier.com", "sciencedirect.com"], "crossmark-restriction": true}, "short-container-title": ["European Journal of Internal Medicine"], "published-print": {"date-parts": [[2017, 1]]}, "DOI": "10.1016/j.ejim.2016.09.026", "type": "journal-article", "created": {"date-parts": [[2016, 10, 11]], "date-time": "2016-10-11T00:42:40Z", "timestamp": 1476146560000}, "page": "e45-e46", "update-policy": "http://dx.doi.org/10.1016/elsevier_cm_policy", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Splenomegaly and the JAK2 V617F mutation"], "prefix": "10.1016", "volume": "37", "author": [{"given": "Stephen E.", "family": "Langabeer", "sequence": "first", "affiliation": []}], "member": "78", "container-title": ["European Journal of Internal Medicine"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S095362051630348X?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S095362051630348X?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 9, 7]], "date-time": "2018-09-07T19:27:47Z", "timestamp": 1536348467000}, "score": 33.473236, "issued": {"date-parts": [[2017, 1]]}, "references-count": 4, "alternative-id": ["S095362051630348X"], "URL": "http://dx.doi.org/10.1016/j.ejim.2016.09.026", "ISSN": ["0953-6205"], "issn-type": [{"value": "0953-6205", "type": "print"}], "assertion": [{"value": "Elsevier", "name": "publisher", "label": "This article is maintained by"}, {"value": "Splenomegaly and the JAK2 V617F mutation", "name": "articletitle", "label": "Article Title"}, {"value": "European Journal of Internal Medicine", "name": "journaltitle", "label": "Journal Title"}, {"value": "https://doi.org/10.1016/j.ejim.2016.09.026", "name": "articlelink", "label": "CrossRef DOI link to publisher maintained version"}, {"value": "simple-article", "name": "content_type", "label": "Content Type"}, {"value": "\u00a9 2016 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.", "name": "copyright", "label": "Copyright"}]}, {"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T06:53:04Z", "timestamp": 1574751184132}, "reference-count": 0, "publisher": "JCDR Research and Publications", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["JCDR"], "DOI": "10.7860/jcdr/2015/16407.6934", "type": "journal-article", "created": {"date-parts": [[2015, 12, 17]], "date-time": "2015-12-17T04:53:18Z", "timestamp": 1450327998000}, "source": "Crossref", "is-referenced-by-count": 0, "title": ["The JAK2 V617F Mutation in Plasma Cell Neoplasms with Co-existing Erythrocytosis"], "prefix": "10.7860", "author": [{"given": "Stephen E", "family": "Langabeer", "sequence": "first", "affiliation": []}], "member": "4601", "published-online": {"date-parts": [[2015]]}, "container-title": ["JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH"], "deposited": {"date-parts": [[2015, 12, 17]], "date-time": "2015-12-17T04:53:18Z", "timestamp": 1450327998000}, "score": 33.473236, "issued": {"date-parts": [[2015]]}, "references-count": 0, "URL": "http://dx.doi.org/10.7860/jcdr/2015/16407.6934", "ISSN": ["2249-782X"], "issn-type": [{"value": "2249-782X", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 12, 3]], "date-time": "2019-12-03T11:37:04Z", "timestamp": 1575373024254}, "reference-count": 5, "publisher": "Wiley", "issue": "3", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2018, 12, 21]], "date-time": "2018-12-21T00:00:00Z", "timestamp": 1545350400000}, "delay-in-days": 0, "content-version": "tdm"}, {"URL": "http://onlinelibrary.wiley.com/termsAndConditions#vor", "start": {"date-parts": [[2018, 12, 21]], "date-time": "2018-12-21T00:00:00Z", "timestamp": 1545350400000}, "delay-in-days": 0, "content-version": "vor"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Clin Exp Dermatol"], "published-print": {"date-parts": [[2019, 4]]}, "DOI": "10.1111/ced.13872", "type": "journal-article", "created": {"date-parts": [[2018, 12, 22]], "date-time": "2018-12-22T01:58:26Z", "timestamp": 1545443906000}, "page": "e33-e33", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Aquagenic pruritus and the JAK2\n V617F mutation"], "prefix": "10.1111", "volume": "44", "author": [{"ORCID": "http://orcid.org/0000-0002-6119-158X", "authenticated-orcid": false, "given": "S. E.", "family": "Langabeer", "sequence": "first", "affiliation": [{"name": "Cancer Molecular Diagnostics; St James's Hospital; Dublin D08 RX0X Ireland"}]}], "member": "311", "published-online": {"date-parts": [[2018, 12, 21]]}, "reference": [{"key": "10.1111/ced.13872-BIB0001|ced13872-cit-0001", "first-page": "602", "article-title": "Aquagenic cutaneous disorders", "volume": "15", "author": "Wang", "year": "2017", "journal-title": "J Dtsch Dermatol Ges"}, {"key": "10.1111/ced.13872-BIB0002|ced13872-cit-0002", "doi-asserted-by": "crossref", "first-page": "255", "DOI": "10.1111/bjd.14809", "article-title": "Clinical characteristics of aquagenic pruritus in patients with myeloproliferative neoplasms", "volume": "176", "author": "Le Gall-Ianotto", "year": "2017", "journal-title": "Br J Dermatol"}, {"key": "10.1111/ced.13872-BIB0003|ced13872-cit-0003", "doi-asserted-by": "crossref", "first-page": "94", "DOI": "10.1002/ajh.24607", "article-title": "Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management", "volume": "92", "author": "Tefferi", "year": "2017", "journal-title": "Am J Hematol"}, {"key": "10.1111/ced.13872-BIB0004|ced13872-cit-0004", "doi-asserted-by": "crossref", "first-page": "34", "DOI": "10.1111/bjd.16117", "article-title": "British Association of Dermatologists\u2019 guidelines for the investigation and management of generalized pruritus in adults without an underlying dermatosis, 2018", "volume": "178", "author": "Millington", "year": "2018", "journal-title": "Br J Dermatol"}, {"key": "10.1111/ced.13872-BIB0005|ced13872-cit-0005", "doi-asserted-by": "crossref", "first-page": "461", "DOI": "10.1016/j.jmoldx.2011.05.007", "article-title": "Use and abuses of JAK2 and MPL mutation tests in myeloproliferative neoplasms", "volume": "13", "author": "Tefferi", "year": "2011", "journal-title": "J Mol Diagn"}], "container-title": ["Clinical and Experimental Dermatology"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fced.13872", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://onlinelibrary.wiley.com/wol1/doi/10.1111/ced.13872/fullpdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 3, 13]], "date-time": "2019-03-13T04:56:11Z", "timestamp": 1552452971000}, "score": 33.473236, "issued": {"date-parts": [[2018, 12, 21]]}, "references-count": 5, "journal-issue": {"published-print": {"date-parts": [[2019, 4]]}, "issue": "3"}, "URL": "http://dx.doi.org/10.1111/ced.13872", "archive": ["Portico"], "relation": {"cites": []}, "ISSN": ["0307-6938"], "issn-type": [{"value": "0307-6938", "type": "print"}], "subject": ["Dermatology"]}, {"indexed": {"date-parts": [[2019, 12, 3]], "date-time": "2019-12-03T15:36:57Z", "timestamp": 1575387417177}, "reference-count": 0, "publisher": "LLC MORION", "issue": "4", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Exp. Onc."], "abstract": "<jats:p>As acquisition of the JAK2 V6\ufffd7F is considered to \ufffde restricted to myeloid malignancies\ufffd the recurrent identification of this mutation in non-small cell lung cancer \ufffdNSCLC\ufffd merits discussion\ufffd particularly in the light of accumulating evidence which suggests that the JAK2 V6\ufffd7F may not \ufffde a true driver mutation of NSCLC.</jats:p>", "DOI": "10.31768/2312-8852.2018.40(4):343-344", "type": "journal-article", "created": {"date-parts": [[2019, 1, 23]], "date-time": "2019-01-23T21:33:53Z", "timestamp": 1548279233000}, "page": "343-344", "source": "Crossref", "is-referenced-by-count": 0, "title": ["THE JAK2 V617F MUTATION IN LUNG CANCER: CAVEAT EMPTOR"], "prefix": "10.32471", "volume": "40", "author": [{"given": "S E", "family": "Langabeer", "sequence": "first", "affiliation": []}], "member": "17358", "published-online": {"date-parts": [[2018, 12, 22]]}, "container-title": ["Experimental Oncology"], "deposited": {"date-parts": [[2019, 4, 5]], "date-time": "2019-04-05T11:49:56Z", "timestamp": 1554464996000}, "score": 33.473236, "issued": {"date-parts": [[2018, 12, 22]]}, "references-count": 0, "journal-issue": {"published-online": {"date-parts": [[2018, 12, 22]]}, "issue": "4"}, "URL": "http://dx.doi.org/10.31768/2312-8852.2018.40(4):343-344", "ISSN": ["2312-8852", "1812-9269"], "issn-type": [{"value": "1812-9269", "type": "print"}, {"value": "2312-8852", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 27]], "date-time": "2019-11-27T07:21:02Z", "timestamp": 1574839262704}, "reference-count": 6, "publisher": "Springer Science and Business Media LLC", "issue": "1", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2017, 9, 24]], "date-time": "2017-09-24T00:00:00Z", "timestamp": 1506211200000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": ["link.springer.com"], "crossmark-restriction": false}, "short-container-title": ["Pathol. Oncol. Res."], "published-print": {"date-parts": [[2019, 1]]}, "DOI": "10.1007/s12253-017-0315-2", "type": "journal-article", "created": {"date-parts": [[2017, 9, 24]], "date-time": "2017-09-24T05:07:32Z", "timestamp": 1506229652000}, "page": "437-438", "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Neutrophilia and the JAK2 V617F Mutation"], "prefix": "10.1007", "volume": "25", "author": [{"given": "Stephen E.", "family": "Langabeer", "sequence": "first", "affiliation": []}, {"given": "Karl", "family": "Haslam", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2017, 9, 24]]}, "reference": [{"key": "315_CR1", "doi-asserted-by": "publisher", "first-page": "2391", "DOI": "10.1182/blood-2016-03-643544", "volume": "127", "author": "DA Arber", "year": "2016", "unstructured": "Arber DA, Orazi A, Hasserjian R et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391\u20132405", "journal-title": "Blood"}, {"key": "315_CR2", "doi-asserted-by": "publisher", "first-page": "1149", "DOI": "10.1136/jclinpath-2012-201008", "volume": "65", "author": "SE Langabeer", "year": "2012", "unstructured": "Langabeer SE (2012) Referral centre variation in requesting JAK2 V617F mutation analysis for the investigation of a myeloproliferative neoplasm. J Clin Pathol 65:1149\u20131150", "journal-title": "J Clin Pathol"}, {"key": "315_CR3", "doi-asserted-by": "publisher", "first-page": "733", "DOI": "10.1016/j.jmoldx.2013.07.002", "volume": "15", "author": "JZ Gong", "year": "2013", "unstructured": "Gong JZ, Cook JR, Greiner RC et al (2013) Laboratory practice guidelines for detecting and reporting JAK2 and MPL mutations in myeloproliferative neoplasms: a report for the Association for Molecular Pathology. J Mol Diagn 15:733\u2013744", "journal-title": "J Mol Diagn"}, {"key": "315_CR4", "doi-asserted-by": "publisher", "first-page": "499", "DOI": "10.1097/SMJ.0b013e31821ec7cc", "volume": "104", "author": "AB Weir", "year": "2011", "unstructured": "Weir AB, Lewis JB Jr, Arteta-Bulos R (2011) Chronic idiopathic neutrophilia: experience and recommendations. South Med J 104:499\u2013504", "journal-title": "South Med J"}, {"key": "315_CR5", "unstructured": "Ogunleye F, Ibrahim M, Allen E et al (2016) BCR-ABL testing by polymerase chain reaction in patients with neutrophilia: the William Beaumont Hospital experience and the case for rational laboratory tests request. J Oncol Pract 12:e1001\u2013e1005", "DOI": "10.1200/JOP.2016.014449", "doi-asserted-by": "crossref"}, {"key": "315_CR6", "doi-asserted-by": "publisher", "first-page": "461", "DOI": "10.1016/j.jmoldx.2011.05.007", "volume": "13", "author": "A Tefferi", "year": "2011", "unstructured": "Tefferi A, Noel P, Hanson CA (2011) Uses and abuses of JAK2 and MPL mutation tests in myeloproliferative neoplasms. J Mol Diagn 13:461\u2013466", "journal-title": "J Mol Diagn"}], "container-title": ["Pathology & Oncology Research"], "language": "en", "link": [{"URL": "http://link.springer.com/article/10.1007/s12253-017-0315-2/fulltext.html", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/content/pdf/10.1007/s12253-017-0315-2.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/content/pdf/10.1007/s12253-017-0315-2.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 9, 6]], "date-time": "2019-09-06T05:27:57Z", "timestamp": 1567747677000}, "score": 33.215427, "issued": {"date-parts": [[2017, 9, 24]]}, "references-count": 6, "journal-issue": {"published-print": {"date-parts": [[2019, 1]]}, "issue": "1"}, "alternative-id": ["315"], "URL": "http://dx.doi.org/10.1007/s12253-017-0315-2", "relation": {"cites": []}, "ISSN": ["1219-4956", "1532-2807"], "issn-type": [{"value": "1219-4956", "type": "print"}, {"value": "1532-2807", "type": "electronic"}], "assertion": [{"value": "2 December 2016", "order": 1, "name": "received", "label": "Received", "group": {"name": "ArticleHistory", "label": "Article History"}}, {"value": "19 September 2017", "order": 2, "name": "accepted", "label": "Accepted", "group": {"name": "ArticleHistory", "label": "Article History"}}, {"value": "24 September 2017", "order": 3, "name": "first_online", "label": "First Online", "group": {"name": "ArticleHistory", "label": "Article History"}}, {"order": 1, "name": "Ethics", "group": {"name": "EthicsHeading", "label": "Compliance with Ethical Standards"}}, {"value": "The authors declare that they have no conflicts of interest.", "order": 2, "name": "Ethics", "group": {"name": "EthicsHeading", "label": "Conflict of Interest"}}]}, {"indexed": {"date-parts": [[2019, 12, 5]], "date-time": "2019-12-05T07:05:20Z", "timestamp": 1575529520031}, "reference-count": 0, "publisher": "American Society of Hematology", "issue": "11", "content-domain": {"domain": ["ashpublications.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[2006, 11, 16]]}, "abstract": "<jats:title>Abstract</jats:title>\n               <jats:p>Small molecule tyrosine kinase inhibitors have had dramatic clinical efficacy in chronic myelogenous leukemia. The identification of a specific activating mutation (V617F) in the gene encoding Janus Kinase 2 (JAK2) in a large proportion of patients with myeloproliferative disorders (MPDs) suggests that a kinase inhibitor might have similar clinical utility. CEP-701 is an orally-active inhibitor of receptor tyrosine kinases including FLT-3, and is currently in phase II clinical trials in acute myeloid leukemia (AML) for patients with FLT-3 mutations. The ability of CEP-701 to inhibit JAK2 and suppress the growth of cells from patients with MPDs was evaluated. In in vitro kinase assay CEP-701 inhibited wild type JAK2 (IC50 l nM). In addition, CEP-701 inhibited:</jats:p>\n               <jats:p>constitutive JAK2/STAT5 signaling in human HEL92.1.7 erythroleukemia cell line homozygous for the V617F mutation (IC50 10 nM); growth of HEL92.1.7 cells in vitro (IC50 of 30\u2013100 nM depending upon assay and serum conditions); and growth of HEL92.1.7 xenografts in nude mice.</jats:p>\n               <jats:p>To test whether these observations could extend to clinical samples from MPD patients, peripheral blood cells from patients with MPDs were collected and CD34+ cells were isolated using immunomagnetic separation. Cells were cultured in the presence of stem cell factor, interleukin 3 and interleukin 6 for 5 days, followed by the addition of erythropoietin for up to 5 days. Between days 7 and 10, cells were incubated in the presence of CEP-701 (up to 300 nM) and proliferation was assayed after 24 to 72 hours using the tetrazolium dye XTT. Flow cytometry and morphological examination confirmed that culture conditions strongly favored erythroid proliferation, with loss of expression of CD45 and the stepwise expression of high levels of CD71 and glycophorin A; cell expansion was more than 100-fold. Concentrations of \u2264100 nM CEP-701 inhibited (&gt; 50%) the growth of cells from 2/4 patients with polycythemia vera (PV), 10/11 with essential thrombocythemia (ET), and 2/2 with agnogenic myeloid metaplasia (AMM), as well as one AML sample from a patient with a prior history of PV. The JAK2 V617F mutation was detected by allele specific PCR and restriction analysis in mononuclear cells from 6 of 11 ET samples (6/10 inhibited), 3 of 4 PV samples (2/2 inhibited) and 1 of 2 AMM samples, as well as the AML sample. In contrast, CD34+ cells from 4 normal bone marrows cultured identically were not significantly inhibited. Biochemical analysis confirmed that in maturing erythroid cells CEP-701, at 30\u2013100 nM, strongly inhibited JAK2/STAT5 and AKT signaling. In addition, CEP-701 suppressed expression of BclxL and cyclin D1/D2, the downstream targets of the JAK2/STAT5 pathway involved in proliferation of progenitor cells. These results demonstrate that in primary cells derived from patients with MPDs, CEP-701, in clinically achievable concentrations, inhibits constitutive JAK2/STAT5 signaling driven by the wild type and V617F JAK2 and inhibits the proliferation of cells from patients with MPDs. CEP-701 holds promise as a therapeutic agent for patients with MPDs.</jats:p>", "DOI": "10.1182/blood.v108.11.3594.3594", "type": "journal-article", "created": {"date-parts": [[2019, 10, 12]], "date-time": "2019-10-12T01:55:01Z", "timestamp": 1570845301000}, "page": "3594-3594", "update-policy": "http://dx.doi.org/10.1182/blood.2019cm0000", "source": "Crossref", "is-referenced-by-count": 1, "title": ["CEP-701 Is a JAK2 Inhibitor Which Attenuates JAK2/STAT5 Signaling Pathway and the Proliferation of Primary Cells from Patients with Myeloproliferative Disorders."], "prefix": "10.1182", "volume": "108", "author": [{"given": "Pawel", "family": "Dobrzanski", "sequence": "first", "affiliation": [{"name": "Discovery Research-Oncology, Cephalon Inc, West Chester, PA, USA"}]}, {"given": "Elizabeth", "family": "Hexner", "sequence": "additional", "affiliation": [{"name": "Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA"}]}, {"given": "Cynthia", "family": "Serdikoff", "sequence": "additional", "affiliation": [{"name": "Discovery Research-Oncology, Cephalon Inc, West Chester, PA, USA"}]}, {"given": "Mahfuza", "family": "Jan", "sequence": "additional", "affiliation": [{"name": "Discovery Research-Oncology, Cephalon Inc, West Chester, PA, USA"}]}, {"given": "Cezary", "family": "Swider", "sequence": "additional", "affiliation": [{"name": "Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA"}]}, {"given": "Candy", "family": "Robinson", "sequence": "additional", "affiliation": [{"name": "Discovery Research-Oncology, Cephalon Inc, West Chester, PA, USA"}]}, {"given": "Shi", "family": "Yang", "sequence": "additional", "affiliation": [{"name": "Discovery Research-Oncology, Cephalon Inc, West Chester, PA, USA"}]}, {"given": "Thelma", "family": "Angeles", "sequence": "additional", "affiliation": [{"name": "Discovery Research-Oncology, Cephalon Inc, West Chester, PA, USA"}]}, {"given": "Stephen G.", "family": "Emerson", "sequence": "additional", "affiliation": [{"name": "Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA"}]}, {"given": "Martin", "family": "Carroll", "sequence": "additional", "affiliation": [{"name": "Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA"}]}, {"given": "Bruce", "family": "Ruggeri", "sequence": "additional", "affiliation": [{"name": "Discovery Research-Oncology, Cephalon Inc, West Chester, PA, USA"}]}], "member": "234", "container-title": ["Blood"], "language": "en", "link": [{"URL": "https://ashpublications.org/blood/article/108/11/3594/127064/CEP701-Is-a-JAK2-Inhibitor-Which-Attenuates", "content-type": "application/pdf", "content-version": "vor", "intended-application": "syndication"}, {"URL": "https://ashpublications.org/blood/article/108/11/3594/127064/CEP701-Is-a-JAK2-Inhibitor-Which-Attenuates", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 18]], "date-time": "2019-11-18T06:27:09Z", "timestamp": 1574058429000}, "score": 33.00586, "issued": {"date-parts": [[2006, 11, 16]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2006, 11, 16]]}, "issue": "11"}, "URL": "http://dx.doi.org/10.1182/blood.v108.11.3594.3594", "ISSN": ["0006-4971", "1528-0020"], "issn-type": [{"value": "0006-4971", "type": "print"}, {"value": "1528-0020", "type": "electronic"}], "subject": ["Immunology", "Cell Biology", "Biochemistry", "Hematology"]}, {"indexed": {"date-parts": [[2019, 11, 25]], "date-time": "2019-11-25T15:34:42Z", "timestamp": 1574696082473}, "reference-count": 4, "publisher": "Springer Science and Business Media LLC", "issue": "2", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2016, 9, 10]], "date-time": "2016-09-10T00:00:00Z", "timestamp": 1473465600000}, "delay-in-days": 0, "content-version": "unspecified"}], "content-domain": {"domain": ["link.springer.com"], "crossmark-restriction": false}, "short-container-title": ["Ir J Med Sci"], "published-print": {"date-parts": [[2017, 5]]}, "DOI": "10.1007/s11845-016-1501-z", "type": "journal-article", "created": {"date-parts": [[2016, 9, 10]], "date-time": "2016-09-10T07:53:33Z", "timestamp": 1473494013000}, "page": "349-350", "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy", "source": "Crossref", "is-referenced-by-count": 0, "title": ["The JAK2 V617F mutation in patients with anaemia"], "prefix": "10.1007", "volume": "186", "author": [{"given": "S. E.", "family": "Langabeer", "sequence": "first", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2016, 9, 10]]}, "reference": [{"key": "1501_CR1", "doi-asserted-by": "crossref", "first-page": "e337", "DOI": "10.1038/bcj.2015.64", "volume": "14", "author": "T Barbui", "year": "2015", "unstructured": "Barbui T, Thiele J, Vannucchi AM, Tefferi A (2015) Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis. Blood Cancer J 14:e337", "journal-title": "Blood Cancer J"}, {"key": "1501_CR2", "doi-asserted-by": "crossref", "first-page": "1117", "DOI": "10.3324/haematol.2014.114660", "volume": "100", "author": "TI Mughal", "year": "2015", "unstructured": "Mughal TI, Cross NC, Padron E et al (2015) An international MDS/MPN working group\u2019s perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms. Haematologica 100:1117\u20131130", "journal-title": "Haematologica"}, {"key": "1501_CR3", "doi-asserted-by": "crossref", "first-page": "18", "DOI": "10.1179/1607845414Y.0000000161", "volume": "20", "author": "BL Gaspar", "year": "2015", "unstructured": "Gaspar BL, Sharma P, Das R (2015) Anemia in malignancies: pathogenetic and diagnostic considerations. Hematology 20:18\u201325", "journal-title": "Hematology"}, {"key": "1501_CR4", "first-page": "189", "volume": "108", "author": "SE Langabeer", "year": "2015", "unstructured": "Langabeer SE (2015) Lack of national consensus for the molecular investigation of myeloproliferative neoplasms. Ir Med J 108:189\u2013190", "journal-title": "Ir Med J"}], "container-title": ["Irish Journal of Medical Science (1971 -)"], "language": "en", "link": [{"URL": "http://link.springer.com/content/pdf/10.1007/s11845-016-1501-z.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/article/10.1007/s11845-016-1501-z/fulltext.html", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/content/pdf/10.1007/s11845-016-1501-z.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2017, 5, 13]], "date-time": "2017-05-13T10:35:48Z", "timestamp": 1494671748000}, "score": 32.824722, "issued": {"date-parts": [[2016, 9, 10]]}, "references-count": 4, "journal-issue": {"published-print": {"date-parts": [[2017, 5]]}, "issue": "2"}, "alternative-id": ["1501"], "URL": "http://dx.doi.org/10.1007/s11845-016-1501-z", "relation": {"cites": []}, "ISSN": ["0021-1265", "1863-4362"], "issn-type": [{"value": "0021-1265", "type": "print"}, {"value": "1863-4362", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T08:14:33Z", "timestamp": 1574496873513}, "reference-count": 0, "publisher": "American Association for Cancer Research", "content-domain": {"domain": ["aacrjournals.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[2010, 4, 15]]}, "DOI": "10.1158/1538-7445.am10-5257", "type": "proceedings-article", "created": {"date-parts": [[2011, 2, 25]], "date-time": "2011-02-25T18:12:40Z", "timestamp": 1298657560000}, "update-policy": "http://dx.doi.org/10.1158/aacr-crossmark-policy", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Abstract 5257: Preclinical evaluation of lestaurtinib (CEP-701) with the retinoids for neuroblastoma"], "prefix": "10.1158", "author": [{"given": "Robin E.", "family": "Norris", "sequence": "first", "affiliation": []}, {"given": "Jane E.", "family": "Minturn", "sequence": "additional", "affiliation": []}, {"given": "Garrett M.", "family": "Brodeur", "sequence": "additional", "affiliation": []}, {"given": "John M.", "family": "Maris", "sequence": "additional", "affiliation": []}, {"given": "Peter C.", "family": "Adamson", "sequence": "additional", "affiliation": []}], "member": "1086", "published-online": {"date-parts": [[2014, 11, 17]]}, "event": {"name": "Proceedings: AACR 101st Annual Meeting 2010\u2010\u2010 Apr 17\u201021, 2010; Washington, DC"}, "container-title": ["Tumor Biology"], "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1158/1538-7445.AM10-5257", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 18]], "date-time": "2019-05-18T17:42:34Z", "timestamp": 1558201354000}, "score": 32.684586, "issued": {"date-parts": [[2010, 4, 15]]}, "references-count": 0, "alternative-id": ["10.1158/1538-7445.AM10-5257"], "URL": "http://dx.doi.org/10.1158/1538-7445.am10-5257"}, {"indexed": {"date-parts": [[2019, 11, 20]], "date-time": "2019-11-20T20:17:15Z", "timestamp": 1574281035727}, "reference-count": 9, "publisher": "Springer Science and Business Media LLC", "issue": "6", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2007, 3, 15]], "date-time": "2007-03-15T00:00:00Z", "timestamp": 1173916800000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Leukemia"], "published-print": {"date-parts": [[2007, 6]]}, "DOI": "10.1038/sj.leu.2404649", "type": "journal-article", "created": {"date-parts": [[2007, 3, 15]], "date-time": "2007-03-15T10:19:09Z", "timestamp": 1173953949000}, "page": "1331-1332", "source": "Crossref", "is-referenced-by-count": 15, "title": ["A higher JAK2 V617F-mutated clone is observed in platelets than in granulocytes from essential thrombocythemia patients, but not in patients with polycythemia vera and primary myelofibrosis"], "prefix": "10.1038", "volume": "21", "author": [{"given": "B", "family": "Bellosillo", "sequence": "first", "affiliation": []}, {"given": "L", "family": "Mart\u00ednez-Avil\u00e9s", "sequence": "additional", "affiliation": []}, {"given": "E", "family": "Gimeno", "sequence": "additional", "affiliation": []}, {"given": "L", "family": "Florensa", "sequence": "additional", "affiliation": []}, {"given": "R", "family": "Longar\u00f3n", "sequence": "additional", "affiliation": []}, {"given": "G", "family": "Navarro", "sequence": "additional", "affiliation": []}, {"given": "A", "family": "Salar", "sequence": "additional", "affiliation": []}, {"given": "B", "family": "Espinet", "sequence": "additional", "affiliation": []}, {"given": "F", "family": "Sol\u00e9", "sequence": "additional", "affiliation": []}, {"given": "S", "family": "Serrano", "sequence": "additional", "affiliation": []}, {"given": "C", "family": "Besses", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2007, 3, 15]]}, "reference": [{"key": "BF2404649_CR1", "doi-asserted-by": "publisher", "first-page": "397", "DOI": "10.2353/jmoldx.2006.060007", "volume": "8", "author": "DP Steensma", "year": "2006", "unstructured": "Steensma DP . JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. J Mol Diagn 2006; 8: 397\u2013411.", "journal-title": "J Mol Diagn"}, {"key": "BF2404649_CR2", "doi-asserted-by": "publisher", "first-page": "1865", "DOI": "10.1182/blood-2006-01-013540", "volume": "108", "author": "E Lippert", "year": "2006", "unstructured": "Lippert E, Boissinot M, Kralovics R, Girodon F, Dobo I, Praloran V et al. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood 2006; 108: 1865\u20131867.", "journal-title": "Blood"}, {"key": "BF2404649_CR3", "doi-asserted-by": "publisher", "first-page": "1903", "DOI": "10.1038/sj.leu.2404341", "volume": "20", "author": "L Florensa", "year": "2006", "unstructured": "Florensa L, Bellosillo B, Besses C, Puigdecanet E, Espinet B, Perez-Vila E et al. JAK2 V617F mutation analysis in different myeloid lineages (granulocytes, platelets, CFU-MK, BFU-E and CFU-GM) in essential thrombocythemia patients. Leukemia 2006; 20: 1903\u20131905.", "journal-title": "Leukemia"}, {"key": "BF2404649_CR4", "doi-asserted-by": "publisher", "first-page": "210", "DOI": "10.1111/j.1600-0609.2006.00688.x", "volume": "77", "author": "PG Heller", "year": "2006", "unstructured": "Heller PG, Lev PR, Salim JP, Kornblihtt LI, Goette NP, Chazarreta CD et al. JAK2V617F mutation in platelets from essential thrombocythemia patients: correlation with clinical features and analysis of STAT5 phosphorylation status. Eur J Haematol 2006; 77: 210\u2013216.", "journal-title": "Eur J Haematol"}, {"key": "BF2404649_CR5", "doi-asserted-by": "publisher", "first-page": "1945", "DOI": "10.1016/S0140-6736(05)67785-9", "volume": "366", "author": "PJ Campbell", "year": "2005", "unstructured": "Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005; 366: 1945\u20131953.", "journal-title": "Lancet"}, {"key": "BF2404649_CR6", "doi-asserted-by": "publisher", "first-page": "3913", "DOI": "10.1182/blood-2006-03-008805", "volume": "108", "author": "AR Moliterno", "year": "2006", "unstructured": "Moliterno AR, Williams DM, Rogers O, Spivak JL . Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression. Blood 2006; 108: 3913\u20133915.", "journal-title": "Blood"}, {"key": "BF2404649_CR7", "doi-asserted-by": "publisher", "first-page": "4139", "DOI": "10.1182/blood-2005-09-3900", "volume": "107", "author": "RL Levine", "year": "2006", "unstructured": "Levine RL, Belisle C, Wadleigh M, Zahrieh D, Lee S, Chagnon P et al. X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis. Blood 2006; 107: 4139\u20134141.", "journal-title": "Blood"}, {"key": "BF2404649_CR8", "doi-asserted-by": "crossref", "first-page": "1054", "DOI": "10.1016/S0140-6736(05)74230-6", "volume": "365", "author": "EJ Baxter", "year": "2005", "unstructured": "Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054\u20131061.", "journal-title": "Lancet"}, {"key": "BF2404649_CR9", "doi-asserted-by": "publisher", "first-page": "1181", "DOI": "10.1038/sj.leu.2404214", "volume": "20", "author": "JJ Kiladjian", "year": "2006", "unstructured": "Kiladjian JJ, Elkassar N, Cassinat B, Hetet G, Giraudier S, Balitrand N et al. Essential thrombocythemias without V617F JAK2 mutation are clonal hematopoietic stem cell disorders. Leukemia 2006; 20: 1181\u20131183.", "journal-title": "Leukemia"}], "container-title": ["Leukemia"], "language": "en", "link": [{"URL": "http://www.nature.com/articles/2404649.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/2404649", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/2404649.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 4, 18]], "date-time": "2019-04-18T11:23:17Z", "timestamp": 1555586597000}, "score": 31.871365, "issued": {"date-parts": [[2007, 3, 15]]}, "references-count": 9, "journal-issue": {"published-print": {"date-parts": [[2007, 6]]}, "issue": "6"}, "alternative-id": ["BF2404649"], "URL": "http://dx.doi.org/10.1038/sj.leu.2404649", "relation": {"cites": []}, "ISSN": ["0887-6924", "1476-5551"], "issn-type": [{"value": "0887-6924", "type": "print"}, {"value": "1476-5551", "type": "electronic"}]}], "items-per-page": 20, "query": {"start-index": 0, "search-terms": null}}}